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A B S T R A C T
Background
The optimal duration of thromboprophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is
common practice to administer prophylaxis using low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) until
discharge from hospital, usually seven to 14 days after surgery. International guidelines recommend extending thromboprophylaxis for
up to 35 days following major orthopaedic surgery but the recommendation is weak due to moderate quality evidence. In addition,
recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have
few known drug interactions. Interest in this topic remains high.
Objectives
To assess the effects of extended-duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE)
in people undergoing elective hip or knee replacement surgery, or hip fracture repair.
Search methods
The Cochrane Vascular Information Specialist searched the Specialised Register (last searchedMay 2015) and CENTRAL (2015, Issue
4). Clinical trials databases were searched for ongoing or unpublished studies.
Selection criteria
Randomised controlled trials assessing extended-duration thromboprophylaxis (five to sevenweeks) using accepted prophylactic doses of
LMWH,UFH, vitamin K antagonists (VKA) or direct oral anticoagulants (DOAC) compared with short-duration thromboprophylaxis
(seven to 14 days) followed by placebo, no treatment or similar extended-duration thromboprophylaxis with LMWH, UFH, VKA or
DOACs in participants undergoing hip or knee replacement or hip fracture repair.
Data collection and analysis
We independently selected trials and extracted data. Disagreements were resolved by discussion. We performed fixed-effect model meta-
analyses with odds ratios (ORs) and 95% confidence intervals (CIs). We used a random-effects model when there was heterogeneity.
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Main results
We included 16 studies (24,930 participants); six compared heparin with placebo, one compared VKA with placebo, two compared
DOACwith placebo, one compared VKAwith heparin, five comparedDOACwith heparin and one compared anticoagulants chosen at
investigators’ discretion with placebo. Three trials included participants undergoing knee replacement. No studies assessed hip fracture
repair.
Trials were generally of good methodological quality. The main reason for unclear risk of bias was insufficient reporting. The quality
of evidence according to GRADE was generally moderate, as some comparisons included a single study, low number of events or
heterogeneity between studies leading to wide CIs.
We showed no difference between extended-duration heparin and placebo in symptomatic VTE (OR 0.59, 95% CI 0.35 to 1.01;
2329 participants; 5 studies; high quality evidence), symptomatic deep vein thrombosis (DVT) (OR 0.73, 95% CI 0.39 to 1.38;
2019 participants; 4 studies; moderate quality evidence), symptomatic pulmonary embolism (PE) (OR 0.61, 95% CI 0.16 to 2.33;
1595 participants; 3 studies; low quality evidence) and major bleeding (OR 0.59, 95% CI 0.14 to 2.46; 2500 participants; 5 studies;
moderate quality evidence). Minor bleeding was increased in the heparin group (OR 2.01, 95% CI 1.43 to 2.81; 2500 participants; 5
studies; high quality evidence). Clinically relevant non-major bleeding was not reported.
We showed no difference between extended-duration VKA and placebo (one study, 360 participants) for symptomatic VTE (OR 0.10,
95% CI 0.01 to 1.94; moderate quality evidence), symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; moderate quality evidence),
symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; moderate quality evidence) and major bleeding (OR 2.89, 95% CI 0.12 to 71.31;
low quality evidence). Clinically relevant non-major bleeding and minor bleeding were not reported.
Extended-duration DOAC showed reduced symptomatic VTE (OR 0.20, 95% CI 0.06 to 0.68; 2419 participants; 1 study; moderate
quality evidence) and symptomatic DVT (OR0.18, 95%CI 0.04 to 0.81; 2459 participants; 2 studies; high quality evidence) compared
to placebo. No differences were found for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; 1733 participants; 1 study; low quality
evidence), major bleeding (OR 1.00, 95% CI 0.06 to 16.02; 2457 participants; 1 study; low quality evidence), clinically relevant non-
major bleeding (OR 1.22, 95% CI 0.76 to 1.95; 2457 participants; 1 study; moderate quality evidence) and minor bleeding (OR 1.18,
95% CI 0.74 to 1.88; 2457 participants; 1 study; moderate quality evidence).
We showed no difference between extended-duration anticoagulants chosen at investigators’ discretion and placebo (one study, 557
participants, low quality evidence) for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74), symptomatic DVT (OR 0.33, 95% CI
0.03 to 3.21), symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13), and major bleeding (OR 5.05, 95% CI 0.24 to 105.76). Clinically
relevant non-major bleeding and minor bleeding were not reported.
We showed no difference between extended-duration VKA and heparin (one study, low quality evidence) for symptomatic VTE (OR
1.64, 95% CI 0.85 to 3.16; 1279 participants), symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; 1279 participants), symptomatic
PE (OR 9.16, 95% CI 0.49 to 170.42; 1279 participants), major bleeding (OR 3.87, 95% CI 1.91 to 7.85; 1272 participants) and
minor bleeding (OR 1.33, 95% CI 0.64 to 2.76; 1279 participants). Clinically relevant non-major bleeding was not reported.
We showed no difference between extended-duration DOAC and heparin for symptomatic VTE (OR 0.70, 95% CI 0.28 to 1.70;
15,977 participants; 5 studies; low quality evidence), symptomatic DVT (OR 0.60, 95% CI 0.11 to 3.27; 15,977 participants; 5
studies; low quality evidence), symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; 14,731 participants; 5 studies; moderate quality
evidence), major bleeding (OR 1.11, 95% CI 0.79 to 1.54; 16,199 participants; 5 studies; high quality evidence), clinically relevant
non-major bleeding (OR 1.08, 95% CI 0.90 to 1.28; 15,241 participants; 4 studies; high quality evidence) and minor bleeding (OR
0.95, 95% CI 0.82 to 1.10; 11,766 participants; 4 studies; high quality evidence).
Authors’ conclusions
Moderate quality evidence suggests extended-duration anticoagulants to prevent VTE should be considered for people undergoing hip
replacement surgery, although the benefit should be weighed against the increased risk of minor bleeding. Further studies are needed
to better understand the association between VTE and extended-duration oral anticoagulants in relation to knee replacement and hip
fracture repair, as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing.
P L A I N L A N G U A G E S U M M A R Y
Anticoagulants taken for longer periods to prevent deep vein thrombosis or pulmonary embolism after hip or knee replacement
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Background
Patients undergoing surgery have an increased risk of developing blood clots in their veins. These clots may be in the deep veins of the leg
(deep vein thrombosis (DVT)) or travel to the lungs (pulmonary embolism (PE)). Venous thromboembolism (VTE) is the combined
term for DVT and PE. Prevention of these blood clots (prophylaxis) after surgery may reduce the risk of postoperative vein clots. These
potential benefits, however, have to be balanced against the associated risks of bleeding. The optimal duration of prophylaxis after total
hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using drugs
such as low-molecular-weight heparin and unfractionated heparin (anticoagulants) until discharge from hospital and for a minimum
of seven to 14 days after surgery. Current international guidelines recommend extending prophylaxis for up to 35 days following
major orthopaedic surgery but recognise that the recommendation is weak due to moderate quality evidence. In addition, new oral
anticoagulants (direct oral anticoagulants (DOAC)) show potential benefits such as taking tablets by mouth instead of injection, lack
of frequent monitoring and few known drug interactions. Interest in this topic therefore remains high.
Study characteristics and key results
A total of 16 studies were included, with 24,930 randomised participants (current until May 2015). The main outcomes of interest
were symptomatic (showing symptoms) VTE, including DVT and PE, and bleeding (major, clinically relevant non-major and minor
bleeding). Six studies compared heparin with placebo, one compared the vitamin K antagonist (VKA) warfarin with placebo, two
compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one study compared using
a variety of anticoagulant treatments with placebo. Only three trials included participants undergoing knee replacement and no studies
included participants undergoing hip fracture repair.
For the comparison heparin versus placebo (six studies) no differences were found between the study arms for symptomatic VTE,
symptomatic DVT, symptomatic PE and major bleeding. Minor bleeding was increased in the heparin group. Clinically relevant non-
major bleeding was not reported.
The comparison VKA versus placebo (one study) and the comparison placebo with anticoagulants chosen at the discretion of the
investigators (one study) showed no differences between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE
and major bleeding. Clinically relevant non-major bleeding and minor bleeding were not reported.
For the comparison DOACs versus placebo (two studies), reduced symptomatic VTE and symptomatic DVT were found in favour
of the DOAC but no differences were found for symptomatic PE, major bleeding, clinically relevant non-major bleeding and minor
bleeding.
Comparing extended-duration VKA with extended-duration LMWH (one study) there was no difference between the study arms for
symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding and minor bleeding. Clinically relevant non-major bleeding
was not reported.
Comparing extended-durationDOACwith extended-duration LMWH(five studies) there was no difference between the study arms for
symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding, clinically relevant non-major bleeding and minor bleeding.
Quality of the evidence
Overall, the included studies were of good methodological quality, with the majority of studies having little risk of bias due to study
design and reporting. The majority of concerns came from lack of reporting of specific details. The quality of the evidence was generally
moderate, either because only one study was included in a comparison, because of few events or because there were a lot of differences
between the findings of the studies meaning that the data were difficult to interpret. Further studies are needed to better understand the
relationship between VTE and extended-duration oral anticoagulants for knee replacement and hip fracture repair as well as outcomes
such as DVT below the knee and above the knee, reoperation, wound infection and healing.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: heparin
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with heparin
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.59
(0.35 to 1.01)
2329
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
33 per 1000 20 per 1000
(12 to 33)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.73
(0.39 to 1.38)
2019
(4 RCTs)
⊕⊕⊕©
MODERATE 1
-
24 per 1000 18 per 1000
(9 to 33)
Symptomatic PE
Treatment durat ion 28 -
42 days
Study populat ion OR 0.61
(0.16 to 2.33)
1595
(3 RCTs)
⊕⊕©©
LOW 12
-
6 per 1000 4 per 1000
(1 to 15)
Bleeding - major
Treatment durat ion 28 -
42 days
Study populat ion OR 0.59
(0.14 to 2.46)
2500
(5 RCTs)
⊕⊕⊕©
MODERATE 1
-
4 per 1000 2 per 1000
(0 to 9)
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Clinically relevant non-
major bleeding
Treatment durat ion 28 -
42 days
see comment - - - not reported
Bleeding - minor
Treatment durat ion 28 -
42 days
Study populat ion OR 2.01
(1.43 to 2.81)
2500
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
46 per 1000 88 per 1000
(65 to 119)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level, low number of events leading to imprecision of results
2 Downgraded by one level, some heterogeneity present (I2 = 49%) leading to wide CIs
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B A C K G R O U N D
Description of the condition
Venous thromboembolism describes the formation of a clot in the
deep veins (deep vein thrombosis or DVT - usually of the lower
extremities) and the subsequent embolisation of the clot to the
pulmonary circulation (pulmonary embolisation or PE) or both.
DVT of the lower limbs is associated with localised pain, swelling
and erythema as well as the development of pulmonary emboli
(PE), and the more localised and chronic post thrombotic syn-
drome. PE presents with shortness of breath, pain on inspiration,
tachycardia and right heart overload, and if untreated, can lead to
circulatory collapse and death.
The incidence of VTE, in mostly white populations, is between
100 and 200 per 100,000 person years (Heit 2015; White 2003).
Of these, it is estimated that 45 to 117 per 100,000 person years
are due to DVT (without PE) and 29 to 78 per 100,000 person
years are due to PE (with or withoutDVT) (Heit 2015). Recurrent
VTE occurs in approximately 7.4% of patients by one year, rising
to 30.4% of patients by 10 years (Cushman 2007; Heit 2015;
White 2003).
Although DVT and PE can occur spontaneously, there are many
risk factors for VTE, including periods of inactivity, dehydration,
hospitalisation, trauma, clotting disorders and previous throm-
bosis, varicose veins with phlebitis, pregnancy, oral combined
hormonal contraceptives, malignancy, obesity, smoking and age
(NICE 2010).
Prophylactic strategies in those deemed to be at risk (for example
those undergoing surgical procedures or prolonged hospital in-
patient stays) are recommended by international guidelines pub-
lished by the National Institute for Health and Care Excellence
(NICE) (NICE 2010; NICE 2012), The American College of
Chest Physicians (ACCP) (Guyatt 2012) and the Scottish Inter-
collegiate Guidelines Network (SIGN) (SIGN 2010) and include
the use of anticoagulation such as LMWH,UFH, oral direct factor
Xa inhibitor (rivaroxaban), oral direct thrombin inhibitor (dabiga-
tran), pentasaccharides (fondaparinux), and mechanical compres-
sion such as compression stockings and intermittent pneumatic
compression devices.
Description of the intervention
It is common practice to administer prophylaxis until discharge
fromhospital, and for aminimumof seven to 14 days after surgery.
However, in patients receiving in-hospital prophylaxis, the preva-
lence of venographic DVT (a blood clot in the leg detected by
venography) is still 15% to 30% at the time of hospital discharge
(Eriksson 1997; Mohr 1993; Nurmohamed 1992) while an addi-
tional 10% to 25% of patients develop new asymptomatic DVT
during the next three to four weeks (Dahl 1997; Fragmin Trial;
French Study; Hirsh 1998). It is estimated, based on the available
literature, that fewer than 10% of patients with venographically
documented DVT will develop symptomatic VTE.
Extended-duration prophylaxis is prophylaxis which starts at ad-
mission and continues well beyond discharge, typically for an ad-
ditional 21 to 28 days after discharge, leading to a period of pro-
phylaxis of approximately 35 days (NICE 2010). Randomised tri-
als have demonstrated that extending prophylaxis beyond the time
of hospital discharge substantially reduces the risk of developing
new asymptomatic thrombi at 30 to 45 days (Dahl 1997; Fragmin
Trial; French Study) and this has led these investigators to recom-
mend that prophylaxis of longer duration should be used in all
patients undergoing total hip replacement (THR).
However, two prospective studies, conducted in patients with-
out known proximal DVT at the time of discharge from hos-
pital, demonstrated that the incidence of new out-of-hospital
symptomatic DVT or pulmonary embolism (PE) without ex-
tended-duration prophylaxis was only approximately 2% after
three months of follow-up (Leclerc 1998; Robinson 1997). This
data suggest that the majority of asymptomatic thrombi remain
clinically silent irrespective of whether extended-duration prophy-
laxis is given. Meanwhile, the impact of extended-duration pro-
phylaxis on symptomatic VTE remains to be clarified. Heit 2000
showed that a significant reduction in symptomatic VTE could
not be demonstrated and therefore concluded that prophylaxis
confined to the in-hospital phase is adequate in most patients.
Why it is important to do this review
Current ACCP and NICE guidelines (Guyatt 2012; NICE 2010)
for the prevention of VTE recommend extending thrombopro-
phylaxis for up to 35 days following major orthopaedic surgery
but recognise that the recommendation is weak due to moderate
quality evidence (Guyatt 2012). In addition, recent oral antico-
agulants that exert effect by direct inhibition of thrombin or acti-
vated factor X lack the need for monitoring and have few known
drug interactions. Differences between anticoagulants for the ex-
tended duration also warrant further investigation. Interest in this
topic therefore remains high.
O B J E C T I V E S
To assess the effects of extended-duration anticoagulant throm-
boprophylaxis for the prevention of venous thromboembolism
(VTE) in people undergoing elective hip or knee replacement
surgery, or hip fracture repair.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomised controlled studies which assessed extended duration
of anticoagulant thromboprophylaxis for the prevention of venous
thromboembolism following total hip or knee replacement or hip
fracture repair.
We defined extended-duration thromboprophylaxis as thrombo-
prophylaxis of duration of five to seven weeks.
We included studies which used objective methods (e.g. ultra-
sound, venogram, V-Q scan) to confirm the diagnosis of symp-
tomatic and asymptomatic VTE (DVT or PE). We included data
on asymptomatic DVT from these studies only if screening was
performed using ascending lower-limb contrast venography. We
included open-label, as well as double-blind studies.
Types of participants
Patients undergoing elective total hip or knee replacement surgery
or hip fracture repair. Patients undergoing revisions of a previous
hip or knee replacement were included.
Types of interventions
We included studies which assessed extended-duration throm-
boprophylaxis (five to seven weeks) using accepted prophylactic
doses of anticoagulants LMWH, UFH, vitamin K antagonists or
direct oral anticoagulants (DOACs) compared with short dura-
tion thromboprophylaxis therapy (seven to 14 days) followed by
placebo or no treatment or similar extended duration of thrombo-
prophylaxis therapy with anticoagulants LMWH, UFH, vitamin
K antagonists or DOACs. Other antithrombotic therapy used in
the prevention of VTE inmajor orthopaedic surgery was excluded.
Types of outcome measures
Primary outcomes
Symptomatic VTE (including DVT and PE)
Secondary outcomes
Total VTE (symptomatic or asymptomatic)
Asymptomatic DVT
Asymptomatic proximal and distal DVT
All-cause mortality
Adverse events
Bleeding events (major, clinically relevant non-major bleeding and
minor bleeding)
Reoperation
Wound infection
Wound healing
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Information Specialist (CIS) searched the
Specialised Register (last searched May 2015) and the Cochrane
Central Register of Controlled Trials (CENTRAL) 2015, Issue
4, part of The Cochrane Library, www.cochranelibrary.com. See
Appendix 1 for details of the search strategy used to search CEN-
TRAL. The Specialised Register is maintained by the CIS and
is constructed from weekly electronic searches of MEDLINE,
EMBASE, CINAHL, AMED, and through handsearching rele-
vant journals. The full list of the databases, journals and con-
ference proceedings which have been searched, as well as the
search strategies used are described in the Specialised Register sec-
tion of the Cochrane Vascular module in The Cochrane Library (
www.cochranelibrary.com).
The CIS searched the following trial databases for details of on-
going and unpublished studies;
World Health Organization International Clinical Trials Registry
http://apps.who.int/trialsearch/
ClinicalTrials.gov http://clinicaltrials.gov/
ISRCTN Register http://www.isrctn.com/
Searching other resources
We searched references sections of relevant reports for further stud-
ies.
Data collection and analysis
Selection of studies
Studies identified in the search were individually evaluated by two
review authors (RF and MS) based on title, abstract or full report
for possible inclusion and any disagreements resolved by discus-
sion.
Data extraction and management
Two review authors (RF and MS) independently extracted data
on study characteristics, efficacy and safety outcomes. Extracted
information included study design, country, setting, intention-
to-treat methods, number of participants randomised, number of
participants excluded post-randomisation, losses to follow up, age,
sex, inclusion criteria, exclusion criteria, treatment and control
details and duration of treatment, primary and secondary out-
comes, funding, and how VTE outcomes were confirmed using
objective methods. Data extracted for study outcomes included
symptomatic VTE (DVT and PE), total VTE (symptomatic and
asymptomatic), asymptomatic DVT documented by ascending
lower limb contrast venography (stratified by proximal (popliteal
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vein and above) and distal (calf vein) DVT, where possible), all-
cause mortality, adverse events and bleeding events (major, clini-
cally relevant non-major and minor bleeding). We also extracted
data for reoperation, wound infection and wound healing. We ac-
cepted the primary study authors’ definitions for DVT, PE and
bleeding events. Any disagreements were resolved through discus-
sion.
Assessment of risk of bias in included studies
RF and MS independently assessed the methodological quality of
included studies using the ’Risk of bias’ tool according to Higgins
2011. The following domains were assessed: selection bias (ran-
dom sequence generation, allocation concealment), performance
bias (blinding of participants andpersonnel), detectionbias (blind-
ing of outcome assessment), attrition bias (incomplete outcome
data), reporting bias (selective reporting) and other bias. We clas-
sified the domains as low risk, high risk, or unclear risk according
to Higgins 2011. Disagreements were resolved by discussion.
Measures of treatment effect
We divided studies into six groups based on the treatment profile.
1. Heparin (LMWH or UFH) versus placebo
2. Vitamin K antagonists versus placebo
3. DOACs versus placebo
4. Anticoagulant chosen at investigators’ discretion versus
placebo
5. Vitamin K antagonists versus heparin (LMWH or UFH)
6. DOACs versus heparin (LMWH or UFH)
We pooled data for each of the comparisons for the outcomes of
symptomatic VTE, total VTE, asymptomatic DVT documented
by ascending lower limb contrast venography, all-cause mortal-
ity, adverse events, bleeding events, reoperation, wound infection
and wound healing. The pooled data for each outcome were used
to create a meta-analysis by calculating odds ratios (ORs) with
95% confidence intervals (CIs), as all outcomes were dichoto-
mous. We used fixed-effect models, unless there was evidence of a
large amount of heterogeneity (see Assessment of heterogeneity),
in which case a random-effects model was implemented.
Unit of analysis issues
The unit of analysis was the individual patient.
Dealing with missing data
Where appropriate we used all randomised participants for the
analysis. However, many of the included studies had many par-
ticipants excluded after randomisation, creating a large disparity
between the number of participants randomised and the number
available for assessment of VTE at the end of the study. After dis-
cussion between the review authors, we decided it was generally in-
appropriate to include all randomised participants in our analysis,
and would use the ’intention-to-treat’ populations as reported by
the studies. This population generally consisted of all participants
that received treatment and had evaluable testing of VTE at the
end of the study. If these values were not available, we utilised the
reported per-protocol data. Where necessary, we contacted study
authors to provide missing data.
Assessment of heterogeneity
A test for heterogeneity examines the null hypothesis that all stud-
ies are evaluating the same effect. For each included meta-analysis
we obtained a value comparing the test statistic with a Chi2 distri-
bution. To help readers assess the consistency of results of studies
in a meta-analysis, Review Manager software (RevMan) (RevMan
2014) includes amethod (I2 statistic) that describes the percentage
of total variation across studies due to heterogeneity rather than
by chance. A value of 0% indicates no observed heterogeneity, and
larger values show increasing heterogeneity (Higgins 2003). For
the purposes of this review, if a meta-analysis was found to have an
I2 value of > 50%, we calculated the ORs using a random-effects
model instead of a fixed-effect model.
Assessment of reporting biases
To detect reporting bias we planned to construct funnel plots for
meta-analyses that included at least 10 studies, as funnel plots with
fewer than 10 studies lack the power to distinguish chance from
real asymmetry (Egger 1997).
Data synthesis
We planned to use fixed-effect models for each meta-analysis
to pool data, unless there was evidence of heterogeneity (see
Assessment of heterogeneity), in which case we planned to use a
random-effects model to derive the ORs and 95% CIs.
Subgroup analysis and investigation of heterogeneity
We pre-specified the following subgroup analyses for the primary
outcome symptomatic VTE:
1. hip replacement versus knee replacement versus hip fracture
repair;
2. according to duration of in-hospital prophylaxis (up to 10
days, 10 to 14 days, 15 days or more) in trials comparing
extended anticoagulant thromboprophylaxis versus placebo or
no treatment;
3. performing mandatory discharge venography versus not
performing mandatory discharge venography in trials comparing
extended anticoagulant thromboprophylaxis versus placebo or
no treatment;
4. patients undergoing revisions of a previous hip or knee
replacement.
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Sensitivity analysis
We conducted sensitivity analyses to further explore the robust-
ness of our results. To identify any study that may have exerted a
disproportionate influence on the summary treatment effect, we
removed studies from the analysis that accounted for over 50% of
the weighted summary statistic, where three or more studies were
included, to see if these heavily-weighted studies altered the find-
ings. We also planned to examine the effect of excluding studies
that were at high risk of bias from the analysis, based on the ’Risk
of bias’ tool.We planned to carry out sensitivity analysis only when
two or more studies remained in the analysis after the removal of
the studies in question.
Summary of findings
We constructed a ’Summary of findings’ table for each comparison
using theGRADEproGDT software (GRADEproGDT 2015) to
present themain findings of the review. We included the outcomes
symptomatic VTE, symptomatic DVT, symptomatic PE, major
bleeding, clinically relevant non-major bleeding and minor bleed-
ing in the ’Summary of findings’ table. We calculated assumed
control intervention risks from the mean number of events in the
control groups of the selected studies for each outcome. The sys-
tem developed by the Grading of Recommendation, Assessment,
Development and Evaluation Working Group (GRADE working
group) was used for grading the quality of evidence as high, mod-
erate, low and very low, based on within-study risk of bias, direct-
ness of evidence, heterogeneity, precision of effects estimates, and
risk of publication bias (Atkins 2004). For completeness, addi-
tional ’Summary of findings’ tables were created for the remaining
outcomes of this review and presented in the appendices.
R E S U L T S
Description of studies
Results of the search
See Figure 1
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Figure 1. Study flow diagram.
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Included studies
We included a total of 16 studies with 24,930 randomised partic-
ipants (ADVANCE 3; Barrellier 2010; Dahl 1997; DaPP Study;
EXTEND Study; Fragmin Trial; French Study; Heit 2000; Kolb
2003; Prandoni 2002; RECORD 1 Trial; RECORD 2 Trial;
RE-NOVATE II Trial; RE-NOVATETrial; SACRE Study; Zhang
2014). Nearly all the included randomised studies were multicen-
tre, with just three recruiting from only a single centre (French
Study; Prandoni 2002; Zhang 2014). Three studies were con-
ducted in France (Barrellier 2010; French Study; SACRE Study),
one study inNorway (Dahl 1997), one inDenmark (DaPP Study),
one in the US (Heit 2000) and another in the US and Canada
(Fragmin Trial), one in Germany and Czech Republic (Kolb
2003), one in Italy (Prandoni 2002), one in China (Zhang 2014)
and six that involved centres inmultiple countries, ranging from16
up to 27 countries (ADVANCE 3; EXTEND Study; RECORD
1 Trial; RECORD 2 Trial; RE-NOVATE II Trial; RE-NOVATE
Trial). The duration of treatment ranged between the studies,
with the majority having treatment periods for an average of 35
days (ADVANCE 3; Barrellier 2010; Dahl 1997; DaPP Study;
EXTENDStudy; Fragmin Trial; French Study; RECORD1Trial;
RECORD 2 Trial; Zhang 2014). Both RE-NOVATE II Trial and
RE-NOVATE Trial had treatment periods of 28 to 35 days. One
study had a four-week post-discharge period on top of a median
nine-day hospital phase (Prandoni 2002). Two studies had six-
week treatment periods (Heit 2000; SACRE Study), with the final
study having a treatment period “up to 42 days” (Kolb 2003).
Heparin versus placebo
A total of six trials with 3221 participants compared heparin with
placebo (Dahl 1997; DaPP Study; Fragmin Trial; French Study;
Heit 2000; Kolb 2003). Four of the studies evaluated partici-
pants undergoing total hip replacement (Dahl 1997; DaPP Study;
Fragmin Trial; French Study), two evaluated a combined group of
hip and knee replacements (Heit 2000; Kolb 2003). Heit 2000
presented results for the hip and knee replacement groups sepa-
rately, while Kolb 2003 presented results for the combined group
only.
Five included studies evaluated LMWHversus placebo: three eval-
uated dalteparin (Dahl 1997; DaPP Study; Fragmin Trial), one
evaluated enoxaparin (French Study) and one evaluated the cer-
toparin (Kolb 2003). Heit 2000 compared the anticoagulant arde-
parin sodium versus placebo. It should be noted that ardeparin has
been removed from the market in the US since 2000, but not for
reasons of efficacy or safety (Dotzel 2002).
Duration of the in-hospital/initial phase ranged from four days to
14 days. Heit 2000 reported four to 10 days, while Dahl 1997
and DaPP Study reported seven days for the initial phase. The
French Study and Kolb 2003 had 14 days for their initial phase.
The Fragmin Trial did not report this timeframe. At the time
of discharge from the hospital or at the end of the initial phase
Dahl 1997, Fragmin Trial and the French Study had mandatory
venography to test for DVT. The DaPP Study did state that they
identified those with DVT at the end of the initial phase, but did
not state their methods. While Heit 2000 and Kolb 2003 did not
use objective methods to test for DVT at the end of the initial
phase of the trial.
Vitamin K antagonists versus placebo
One trial with 360 participants compared the VKA antagonist
warfarin with placebo (Prandoni 2002). Prandoni 2002 evaluated
participants undergoing total hip replacement.Duration of the in-
hospital/initial phase had a median of nine days (Prandoni 2002).
At the time of discharge from the hospital Prandoni 2002 per-
formed ultrasonography on all participants to determine incidence
of DVT before the second phase of the trial.
DOACs versus placebo
Two trials with 2549 participants compared DOACs with placebo
(RECORD 2 Trial; Zhang 2014). Both studies evaluated partici-
pants undergoing total hip replacement (RECORD 2Trial; Zhang
2014).
The RECORD 2 Trial compared the oral anticoagulant rivarox-
aban with enoxaparin in the initial phase, then the enoxaparin
group began taking placebo. Zhang 2014 evaluated rivaroxaban
compared with no treatment. Duration of the in-hospital/initial
phase was reported by Zhang 2014 as seven days for the initial
phase while RECORD 2 Trial reported 10 to 14 days. At the end
of the initial phase Zhang 2014 performed ultrasonography on
all participants to determine incidence of DVT before the second
phase of the trial. The RECORD 2 Trial did not use objective
methods to test for DVT at the end of the initial phase of the trial.
Anticoagulant treatments chosen at the investigators’
discretion versus placebo
One trial with 857 participants compared thromboprophylaxis
using anticoagulant treatments chosen at the investigators’ discre-
tion with placebo in participants undergoing total knee replace-
ment (Barrellier 2010). The anticoagulation treatment was either
heparin, enoxaparin, dalteparin, tinzaparin, nadroparin or fonda-
parinux (Barrellier 2010).Duration of the in-hospital/initial phase
was reported as 10 days. At the end of the initial phase Barrellier
2010 performed ultrasonography on all participants to determine
incidence of DVT before the second phase of the trial.
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Vitamin K antagonists versus heparin
One study with a total of 1289 randomised participants evaluated
acenocoumarol versus reviparin sodium (SACRE Study). All par-
ticipants began on the LMWH reviparin sodium until 3 ± 1 days
after surgery when participants were randomised to either con-
tinue on reviparin sodium or cross over to acenocoumarol for six
weeks. Participants showing clinical signs or symptoms of DVT,
PE or major bleeding were not randomised. It is not clear whether
those experiencing clinical signs or symptoms of DVT and PE at
the randomisation stage underwent objective testing using venog-
raphy or duplex scanning. The SACRE Study randomised partic-
ipants undergoing a total hip replacement.
DOACs versus heparin
Five studies with a total of 16,654 randomised participants eval-
uated DOAC versus heparin therapy (ADVANCE 3; EXTEND
Study; RECORD 1 Trial; RE-NOVATE II Trial; RE-NOVATE
Trial). All five studies evaluated participants undergoing a total
hip replacement.One study compared apixaban versus enoxaparin
(ADVANCE 3). One study evaluated ximelagatran versus enoxa-
parin (EXTENDStudy), although this study was terminated early
due to safety concerns with ximelagatran. Two studies compared
dabigatran etexilate with enoxaparin, one with two doses of dabi-
gatran of 220 mg and 150 mg (RE-NOVATE Trial) and the other
only evaluated the 220 mg dosage (RE-NOVATE II Trial). Ri-
varoxaban was compared to enoxaparin in one study (RECORD1
Trial). As these five studies compared two different anticoagulant
treatments and randomised participants prior to surgery, there was
no initial phase and objective assessment of VTE after initial phase
as seen in the studies described above comparing anticoagulants
versus placebo.
Excluded studies
A total of seven studies were assessed as excluded (Comp 2001;
EPCAT II; Kristensen 1990; Manganelli 1998; NPHDO Study
Group; PENTHIFRA PLUS Study; Swedish Study). Six stud-
ies had extended duration, but did not meet the five week min-
imum requirement (Comp 2001; EPCAT II; Manganelli 1998;
NPHDO Study Group; PENTHIFRA PLUS Study; Swedish
Study). Kristensen 1990 did not evaluate a treatment comparison
within the scope of this review: heparin plus indomethacin versus
heparin plus placebo.
A total of 175 records were deemed not relevant mainly due to the
duration of the thromboprophylaxis being 10 to 14 days and not
extended duration.
Risk of bias in included studies
See Figure 2 and Figure 3 for further information on risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall risk of bias was moderate to low with the largest concerns
being some studies either not reporting on listed outcomes or re-
porting outcomes they did not pre-define, leading to selective re-
porting bias, and other bias, mainly stemming from early termi-
nation or potential conflicts of interest due to the involvement of
pharmaceutical companies.
Allocation
Adequate random sequence generation was described in the ma-
jority of studies, but two studies did not provide enough detail to
make an assessment, and were rated as unclear (Dahl 1997; Kolb
2003).
Likewise, nearly all studies provided enough information to de-
termine if allocation concealment was adequate, yet four studies
did not give enough detail (Dahl 1997; DaPP Study; Kolb 2003;
Zhang 2014).
Blinding
Performance bias was generally low as most studies were double-
blind and utilised a placebo. However, four studies were given an
unclear rating as one study was open-label (Barrellier 2010) and
three studies did not state either way if they were open-label or
double-blind, but as noplacebowas acknowledged, theyweremost
likely open-label (Prandoni 2002; SACRE Study; Zhang 2014).
It is unclear if knowing the treatment would have an effect on the
outcomes.
All studies, except for two (Kolb 2003;Zhang2014) used a blinded
assessor or committee to evaluate at least some, if not all, outcomes.
Kolb 2003 and Zhang 2014 may have used blinded assessors, but
no details were given.
Incomplete outcome data
Twelve of the 16 included studies had low risk of attrition bias
as all participants were accounted for in the analysis, and thor-
ough explanations were given for exclusions. Four studies, while
all participants were accounted for, did not give adequate explana-
tions for why some participants stopped taking their medication
or never started (EXTEND Study; RECORD 1 Trial; RECORD
2 Trial; RE-NOVATE II Trial).
Selective reporting
The majority of studies had no evidence of reporting bias, but
two were rated as high risk of bias because one study had bleeding
events listed as an outcome but did not fully report the number of
events (Barrellier 2010) and the other reported on several outcomes
that were not listed as a pre-planned outcome (Dahl 1997). The
EXTEND Study was given an unclear rating as defined outcomes
were not reported on after early termination of the trial.
Other potential sources of bias
Two studies were given a high risk of other bias as one study was
terminated early due to safety issues and also the funding phar-
maceutical company was highly involved in the study design, data
collection and analysis (EXTEND Study), and the other study
was also terminated early because they had a very high statisti-
cal significance with the first 360 enrolled participants (Prandoni
2002). A further four studies also had pharmaceutical companies
as funding bodies that were very involved in the design, data col-
lection and analysis of the studies, which could be a conflict of
interest (ADVANCE 3; RECORD 1 Trial; RECORD 2 Trial;
RE-NOVATE II Trial).
Effects of interventions
See: Summary of findings for the main comparison Heparin
compared to placebo for prevention of venous thromboembolism
following total hip or knee replacement or hip fracture repair;
Summary of findings 2 Vitamin K antagonists compared to
placebo for prevention of venous thromboembolism following
total hip or knee replacement or hip fracture repair; Summary
of findings 3 DOAC compared to placebo for prevention of
venous thromboembolism following total hip or knee replacement
or hip fracture repair; Summary of findings 4 Anticoagulants
(chosen at investigators’ discretion) compared to placebo for
prevention of venous thromboembolism following total hip or
knee replacement or hip fracture repair; Summary of findings
5 Vitamin K antagonists compared to heparin for prevention
of venous thromboembolism following total hip or knee
replacementor hip fracture repair;Summary offindings 6DOAC
compared to heparin for people requiring prevention of venous
thromboembolism following total hip or knee replacement or hip
fracture repair
Heparin versus placebo
See Summary of findings for the main comparison and Appendix
2
Symptomatic VTE (DVT and PE)
Five studies assessed symptomatic VTE (Dahl 1997; Fragmin
Trial; French Study; Heit 2000; Kolb 2003) and the fixed-effect
model found no difference between the study arms:OR0.59, 95%
CI 0.35 to 1.01; participants = 2329; studies = 5; I2 = 0%; high
quality evidence; Analysis 1.1.
Subgroup analysis by hip or knee replacement showed no dif-
ferences between the subgroups and no differences between hep-
arin and placebo were observed for the individual surgery groups
(Analysis 1.1).
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The findings did not change in studies with an in-hospital or initial
phase of 10 to 14 days, or with less than 10 days of in-hospital/
initial phase or when the studies that did not have mandatory,
objective detection of DVT at hospital discharge were excluded
(data analyses not shown).
Symptomatic DVT
Four studies assessed symptomaticDVT (distal or proximal) (Dahl
1997; Fragmin Trial; French Study; Heit 2000) and the fixed-
effect model found no difference between the study arms: OR
0.73, 95% CI 0.39 to 1.38; participants = 2019; studies = 4; I2 =
0%; moderate quality evidence; Analysis 1.2.
Subgroup analysis by hip or knee replacement showed no dif-
ferences between the subgroups and no differences between hep-
arin and placebo were observed for the individual surgery groups
(Analysis 1.2).
The findings did not change in studies with an in-hospital or initial
phase of 10 to 14 days, or with less than 10 days of in-hospital/
initial phase or when the studies that did not have mandatory,
objective detection of DVT at hospital discharge were excluded
(data analyses not shown).
Symptomatic PE
The fixed-effect model evaluating three studies for symptomatic
PE (Dahl 1997; French Study; Heit 2000), showed no difference
between heparin or placebo (OR 0.61, 95% CI 0.16 to 2.33;
participants = 1595; studies = 3; I2 = 49%; low quality evidence)
Analysis 1.3.
Subgroup analysis by hip or knee replacement showed no dif-
ferences between the subgroups and no differences between hep-
arin and placebo were observed for the individual surgery groups
(Analysis 1.3).
The findings did not change in studies with an in-hospital or initial
phase of 10 to 14 days, or with less than 10 days of in-hospital/
initial phase or when the studies that did not have mandatory,
objective detection of DVT at hospital discharge were excluded
(data analyses not shown).
Regarding sensitivity analysis, Dahl 1997 was found to account
for 64.1% of the participants within this outcome, but after its
removal no difference was seen in the findings.
Total VTE (symptomatic or asymptomatic)
For the six reporting studies (Dahl 1997; DaPP Study; Fragmin
Trial; French Study;Heit 2000; Kolb 2003), the fixed-effectmodel
found decreased odds of any VTE event in favour of heparin (OR
0.39, 95% CI 0.28 to 0.56; participants = 2544; studies = 6; I2 =
0%; high quality evidence) Analysis 1.4.
For the five studies reporting on hip replacement, the fixed-effect
model found decreased odds in favour of heparin (OR 0.37, 95%
CI 0.25 to 0.56; participants = 1511; studies = 5; I2 = 0%) Analysis
1.4. The single study reporting on knee replacement found no
difference between the study arms (OR0.78, 95%CI 0.21 to 2.92;
participants = 723) Analysis 1.4. The single study reporting on a
combined group of hip or knee replacement participants found
decreased odds in favour of heparin (OR 0.38, 95% CI 0.16 to
0.90; participants = 310) Analysis 1.4.
When comparing the subgroup of studies evaluating 10 to 14
day in-hospital/initial phase treatment duration and those that
included objective DVT screening at discharge, the findings were
still in favour of heparin treatment (data analyses not shown).
Asymptomatic DVT
In the five studies that reported on asymptomatic DVT (Dahl
1997; DaPP Study; Fragmin Trial; French Study; Kolb 2003), the
fixed-effect model showed a decreased odds favouring the heparin
treatment group (OR 0.38, 95% CI 0.24 to 0.60; participants =
1304; studies = 5; I2 = 0%; high quality evidence) Analysis 1.5.
When evaluating hip replacement only, the four included studies
retained a decreased odds of asymptomatic DVT (OR 0.35, 95%
CI 0.21 to 0.58; participants = 994; studies = 4; I2 = 0%) Analysis
1.5. The single study reporting on a combined group of hip or
knee replacement participants found no difference between the
study arms (OR 0.54, 95% CI 0.19 to 1.52; participants = 310)
Analysis 1.5.
When comparing the subgroup of studies evaluating 10 to 14
day in-hospital/initial phase treatment duration and those that
included objective DVT screening at discharge, the findings were
still in favour of heparin treatment (data analyses not shown).
Asymptomatic proximal DVT
None of the included studies reported on asymptomatic proximal
DVT.Manydid report asymptomatic or proximalDVTseparately,
but given the provided data, it was not possible to determine which
events fell into both categories.
Asymptomatic distal DVT
No studies reported asymptomatic distal DVT. See above descrip-
tion. Many did report asymptomatic or distal DVT separately, but
given the provided data, it was not possible to determine which
events fell into both categories.
All-cause mortality
For the five included studies that evaluated all-cause mortality for
heparin versus placebo (Dahl 1997; Fragmin Trial; French Study;
Heit 2000; Kolb 2003), there was no difference between the study
arms (OR 1.01, 95%CI 0.31 to 3.26; participants = 2518; studies
= 5; I2 = 0%; moderate quality evidence) Analysis 1.6.
There was also no difference in the four studies evaluating par-
ticipants undergoing hip replacement (OR 0.56, 95% CI 0.11 to
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2.75; participants = 1485; studies = 4; I2 = 0%) Analysis 1.6, or
in the one study undergoing knee replacement (OR 0.98, 95%
CI 0.06 to 15.65; participants = 723) Analysis 1.6. The single
study reporting on a combined group of hip or knee replacement
participants also found no difference between the study arms (OR
4.69, 95% CI 0.22 to 98.42; participants = 310) Analysis 1.6.
When only evaluating studies that had an in-hospital/initial phase
of 10 to 14days or studies that included objectiveDVTverification
at discharge, there was still no difference between study arms (data
analysis not shown).
Adverse events
Only two studies evaluating participants undergoing hip replace-
ment reported on adverse events (DaPP Study; French Study) and
found no difference between study arms (OR 1.06, 95% CI 0.68
to 1.64; participants = 460; I2 = 4%; moderate quality evidence
Analysis 1.7), although it should be noted that there was minimal
or no description of the criteria for adverse event reporting, and it
varied greatly between the two reporting studies.
Too few studies remained for subgroup analysis by initial phase
duration or objective DVT verification at discharge (data analyses
not shown).
Bleeding events (major, clinically relevant non-major, minor)
Major bleeding was reported in five studies (DaPP Study; Fragmin
Trial; French Study; Heit 2000; Kolb 2003) and minor bleed-
ing was reported in five studies (DaPP Study; Fragmin Trial;
French Study; Heit 2000; Kolb 2003). Clinically relevant non-
major bleeding was not reported by the included studies compar-
ing heparin and placebo.
There was no difference inmajor bleeding between the study arms
(OR 0.59, 95% CI 0.14 to 2.46; participants = 2500; studies = 5;
I2 = 0%; moderate quality evidence Analysis 1.8.
For participants undergoing hip replacement, there was no dif-
ference in major bleeding (OR 0.32, 95% CI 0.03 to 3.10; par-
ticipants = 1494; studies = 4; I2 = 0% Analysis 1.8. There was
no difference in major bleeding in participants undergoing knee
replacement (OR 0.99, 95% CI 0.14 to 7.06; participants = 696;
studies = 1; I2 = 0% Analysis 1.8). The single study reporting on a
combined group of hip or knee replacement participants reported
no major bleeding in either study arm (0/161 heparin versus 0/
149 placebo).
There was an increased odds of minor bleeding in the heparin
treatment group compared with placebo (OR 2.01, 95% CI 1.43
to 2.81; participants = 2500; studies = 5; I2 = 0%; high quality
evidence) Analysis 1.9.
For participants undergoing hip replacement, there was an in-
creased odds of minor bleeding in the heparin treatment group
compared with placebo (OR 2.25, 95% CI 1.53 to 3.30; partic-
ipants = 1494; studies = 4; I2 = 0%) Analysis 1.9. There was no
difference in minor bleeding in participants undergoing knee re-
placement (OR 1.23, 95% CI 0.58 to 2.59; participants = 696;
studies = 1Analysis 1.9). The single study reporting on a combined
group of hip and knee replacement participants also reported no
difference in minor bleeding in both study arms (OR 2.79, 95%
CI 0.11 to 69.13; participants = 310; studies = 1; I2 = 0%) Analysis
1.9.
There were no changes to the findings when only comparing stud-
ies with a in-hospital/initial phase of 10 to 14 days or studies that
had objective DVT testing at discharge (data analyses not shown).
Reoperation
The DaPP Study reported that two participants required reoper-
ation but did not report from which study arm. Dahl 1997 re-
ported reoperation due to bleeding to be a safety outcome but did
not present data. The Fragmin Trial, Heit 2000 and Kolb 2003
did not report on reoperation. The French Study reported that no
reoperations were required following bleeding Analysis 1.10.
Wound infection
DaPP Study, French Study, Heit 2000 and Kolb 2003 did not
report on wound infection. Dahl 1997 reported that the majority
of adverse events were luxation of prosthesis and infection but
did not report specific numbers for the study arms. The Fragmin
Trial reported wound infection as part of complications associated
with wound haematoma but no specific details for infection were
provided.
Wound healing
None of the six studies comparing heparin with placebo reported
wound healing (Dahl 1997; DaPP Study; Fragmin Trial; French
Study; Heit 2000; Kolb 2003).
Vitamin K antagonists versus placebo
One study evaluated vitamin K antagonist versus placebo (
Prandoni 2002), in participants undergoing hip replacement, and
therefore no subgroup analysis between hip and knee replacement
was undertaken. We found no difference between the treatment
groups for any of the evaluated outcomes except for total VTE.
See Summary of findings 2 and Appendix 3.
Symptomatic VTE (DVT and PE)
No difference between VKA and placebo was observed for symp-
tomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; participants = 360;
moderate quality evidence) Analysis 2.1.
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Symptomatic DVT
No difference between VKA and placebo was observed for symp-
tomatic DVT (OR 0.13, 95%CI 0.01 to 2.62; participants = 360;
moderate quality evidence) Analysis 2.2.
Symptomatic PE
No difference between VKA and placebo was observed for symp-
tomatic PE (OR 0.32, 95% CI 0.01 to 7.84; participants = 360;
moderate quality evidence) Analysis 2.3.
Total VTE (symptomatic or asymptomatic)
Prandoni 2002 showed decreased odds of any VTE event in favour
of VKA versus placebo (OR 0.10, 95% CI 0.01 to 0.81; partici-
pants = 360; moderate quality evidence) Analysis 2.4.
Asymptomatic DVT
Prandoni 2002 did not report on asymptomatic DVT.
Asymptomatic proximal DVT
Prandoni 2002 did not report on asymptomatic proximal DVT.
Asymptomatic distal DVT
Prandoni 2002 did not report on asymptomatic distal DVT.
All-cause mortality
Prandoni 2002 reported no deaths in either study arm (0/184
VKA versus 0/176 placebo) Analysis 2.5.
Adverse events
Prandoni 2002 reported no adverse events in either study arm (0/
184 VKA versus 0/176 placebo) Analysis 2.6.
Bleeding events (major, clinically relevant non-major, minor)
There were no differences between the study arms in major bleed-
ing (OR 2.89, 95% CI 0.12 to 71.31; participants = 360; low
quality evidence) Analysis 2.7. Prandoni 2002 did not report clin-
ically relevant non-major bleeding or minor bleeding.
Reoperation
Prandoni 2002 did not report on reoperation.
Wound infection
Prandoni 2002 did not report on wound infection
Wound healing
Prandoni 2002 did not report on wound healing.
DOACs versus placebo
Two studies evaluated DOACs versus placebo (RECORD 2 Trial;
Zhang 2014) in participants undergoing hip replacement, and
therefore no subgroup analysis between hip and knee replacement
was undertaken. Zhang 2014 reported assessment of symptomatic
DVT only and is therefore only included in the analysis for symp-
tomatic DVT. See Summary of findings 3 and Appendix 4.
Symptomatic VTE (DVT and PE)
The RECORD 2 Trial reported on symptomatic VTE showing
a reduced odds of VTE in favour of the DOAC treatment (OR
0.20, 95% CI 0.06 to 0.68; participants = 2419; moderate quality
evidence) Analysis 3.1.
Symptomatic DVT
A reduced odds of symptomatic DVT in favour of DOAC treat-
ment was observed (OR 0.18, 95% CI 0.04 to 0.81; participants
= 2459; studies = 2; I2 = not applicable; high quality evidence)
Analysis 3.2
Symptomatic PE
No difference between DOACs and placebo was observed for
symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; participants =
1733; studies = 1; low quality evidence) Analysis 3.3.
Total VTE (symptomatic or asymptomatic)
The RECORD 2 Trial showed decreased odds of any VTE event
in favour of DOAC treatment versus placebo (OR 0.19, 95% CI
0.11 to 0.33; moderate quality evidence) Analysis 3.4.
Asymptomatic DVT
The RECORD 2 Trial and Zhang 2014 do not report on asymp-
tomatic DVT.
Asymptomatic proximal DVT
The RECORD 2 Trial and Zhang 2014 do not report on asymp-
tomatic proximal DVT.
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Asymptomatic distal DVT
The RECORD 2 Trial and Zhang 2014 do not report on asymp-
tomatic distal DVT.
All-cause mortality
There were no differences between the study arms in all-cause
mortality (OR 0.33, 95% CI 0.07 to 1.66; participants = 1733;
studies = 1; low quality evidence Analysis 3.5.
Adverse events
The RECORD 2 Trial reported no differences in adverse events
(OR 0.87, 95% CI 0.74 to 1.03; participants = 2457; moderate
quality evidence) Analysis 3.6.
Bleeding events (major, clinically relevant non-major, minor)
There were no differences in any of the bleeding event categories
reported by RECORD 2 Trial; major bleeding (OR 1.00, 95% CI
0.06 to 16.02; participants = 2457; low quality evidence Analysis
3.7); clinically relevant bleeding (OR 1.22, 95% CI 0.76 to 1.95;
participants = 2457; moderate quality evidence Analysis 3.8); mi-
nor bleeding (OR 1.18, 95%CI 0.74 to 1.88; participants = 2457;
moderate quality evidence Analysis 3.9.
Reoperation
The RECORD 2 Trial reported reoperation following bleeding;
no cases of reoperation (0/1228 DOAC versus 0/1229 placebo)
were reported Analysis 3.10.
Wound infection
The RECORD 2 Trial reported no differences in post-operative
wound infections (OR 1.34, 95% CI 0.46 to 3.86; participants =
2457; low quality evidence) Analysis 3.11.
Wound healing
The RECORD 2 Trial and Zhang 2014 did not report wound
healing.
Anticoagulant treatments chosen at the
investigators’ discretion versus placebo
One study evaluated anticoagulant treatment chosen at the inves-
tigators’ discretion versus placebo (Barrellier 2010) in participants
undergoing knee replacement, and therefore no subgroup analy-
sis between hip and knee replacement was undertaken. The anti-
coagulation treatment was either heparin, enoxaparin, dalteparin,
tinzaparin, nadroparin or fondaparinux, at the discretion of the
investigator at the study location. See Summary of findings 4 and
Appendix 5.
Symptomatic VTE (DVT and PE)
No difference between anticoagulant treatment and placebo was
observed for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74;
participants = 557; low quality evidence) Analysis 4.1.
Symptomatic DVT
No difference between anticoagulant treatment and placebo was
observed for symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21;
participants = 557; low quality evidence) Analysis 4.2.
Symptomatic PE
No difference between anticoagulant treatment and placebo was
observed for symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13;
participants = 557; low quality evidence) Analysis 4.3.
Total VTE (symptomatic or asymptomatic)
The Barrellier 2010 study showed decreased odds of any VTE
event in favour of anticoagulant treatment versus placebo (OR
0.26, 95% CI 0.14 to 0.50; participants = 557; moderate quality
evidence) Analysis 4.4.
Asymptomatic DVT
Barrellier 2010 showed a significant difference in new cases of
asymptomatic DVT favouring anticoagulant treatment compared
to placebo (OR 0.26, 95% CI 0.13 to 0.54; participants = 557;
moderate quality evidence) Analysis 4.5. Barrellier 2010 reported
on asymptomatic distal DVT cases only.
Asymptomatic proximal DVT
Barrellier 2010 did not report asymptomatic proximal DVT.
Asymptomatic distal DVT
Barrellier 2010 reported asymptomatic distal DVT as described
above (Analysis 4.6).
All-cause mortality
Barrellier 2010 reported no deaths in either study arm (0/422
anticoagulant treatment versus 0/420 placebo) Analysis 4.7.
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Adverse events
Barrellier 2010 did not report adverse events.
Bleeding events (major, clinically relevant non-major, minor)
There were no differences between the treatment groups in major
bleeding (OR 5.05, 95% CI 0.24 to 105.76; participants = 557;
low quality evidence). Analysis 4.8. Barrellier 2010 did not report
clinically relevant non-major bleeding or minor bleeding.
Reoperation
Barrellier 2010 reported on reoperation as part of their definition
of major bleeding outcome (bleeding leading to reoperation) but
did not report this data separately.
Wound infection
Barrellier 2010 did not report on wound infection.
Wound healing
Barrellier 2010 did not report on wound healing.
Vitamin K antagonists versus heparin
One study evaluated vitamin K antagonists versus heparin (
SACRE Study) in participants undergoing hip replacement, and
therefore no subgroup analysis between hip and knee replacement
was undertaken. We found no difference between the treatment
groups for any of the evaluated outcomes. See Summary of findings
5 and Appendix 6.
Symptomatic VTE (DVT and PE)
No difference was observed in symptomatic VTE between the
treatment groups (OR 1.64, 95% CI 0.85 to 3.16; participants =
1279; low quality evidence) Analysis 5.1.
Symptomatic DVT
There was also no difference between the treatment groups for
symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; participants
= 1279; low quality evidence) Analysis 5.2.
Symptomatic PE
No cases of PE were reported in the heparin group (0/643) com-
pared with 4 cases in the VKA group (4/636) . No difference was
found between the treatment groups for the outcome of symp-
tomatic PE (OR 9.16, 95% CI 0.49 to 170.42; participants =
1279; low quality evidence) Analysis 5.3.
Total VTE (symptomatic or asymptomatic)
There was no difference in total VTE between the treatment
groups (OR 1.64, 95% CI 0.85 to 3.16; participants = 1279; low
quality evidence) Analysis 5.4 .
Asymptomatic DVT
The SACRE Study did not report asymptomatic DVT.
Asymptomatic proximal DVT
The SACRE Study did not report asymptomatic proximal DVT.
Asymptomatic distal DVT
The SACRE Study did not report asymptomatic distal DVT.
All-cause mortality
Nocases of death were reported in the heparin group (0/643) com-
pared with 2 cases in the VKA group (2/636). There was no dif-
ference in all-cause mortality between the treatment groups (OR
5.07, 95% CI 0.24 to 105.83; participants = 1279; low quality
evidence) Analysis 5.5.
Adverse events
The SACRE Study did not report adverse events.
Bleeding events (major, clinically relevant non-major, minor)
There were no differences between the treatment groups in major
or minor bleeding (OR 3.87, 95% CI 1.91 to 7.85; participants =
1272; low quality evidence, Analysis 5.6, and OR 1.33, 95% CI
0.64 to 2.76; participants = 1279; low quality evidence Analysis
5.7, respectively). The SACRE Study did not report clinically rel-
evant non-major bleeding.
Reoperation
The SACRE Study reported on reoperation as part of their defini-
tion of major bleeding outcome (bleeding leading to reoperation;
reoperation was required in 11 participants (two in the reviparin
group and nine in the acecoumarol group (OR 4.60, 95%CI 0.99
to 21.38; participants = 1279; low quality evidence).
Wound infection
The SACRE Study did not report wound infection.
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Wound healing
The SACRE Study did not report wound healing.
DOACs versus heparin
Five studies evaluated DOACs versus heparin therapy (
ADVANCE 3; EXTEND Study; RECORD 1 Trial; RE-
NOVATE II Trial; RE-NOVATE Trial). The studies evaluating
DOACs versus heparin were only performed in participants un-
dergoing hip replacement, and therefore no subgroup analysis be-
tween hip and knee replacement was undertaken. As these studies
compared two different anticoagulant treatments and randomised
participants prior to surgery, there was no initial phase and ob-
jective assessment of VTE after the initial phase. Therefore these
subgroup analyses were not possible. We found no difference be-
tween the treatment groups for most of the evaluated outcomes.
Due to heterogeneity in the data, some of the meta-analyses in
this treatment profile used random-effects models. See Summary
of findings 6 and Appendix 7.
Symptomatic VTE (DVT and PE)
The random-effects model evaluating five studies (ADVANCE
3; EXTEND Study; RECORD 1 Trial; RE-NOVATE II Trial;
RE-NOVATE Trial) found no difference in symptomatic VTE
between the treatment groups (OR 0.70, 95% CI 0.28 to 1.70;
participants = 15,977; I2 = 55%; low quality evidence) Analysis
6.1.
Symptomatic DVT
There was no difference between the treatment groups for symp-
tomatic DVT, as evaluated by the random-effects model in five
studies (ADVANCE 3; EXTEND Study; RECORD 1 Trial;
RE-NOVATE II Trial; RE-NOVATE Trial) (OR 0.60, 95% CI
0.11 to 3.27; participants = 15,977; I2 = 65%; low quality evi-
dence) Analysis 6.2.
Symptomatic PE
No difference was found between the DOAC and LMWH treat-
ment groups for the outcome of symptomatic PE (OR 0.91, 95%
CI 0.43 to 1.94; participants = 14,731; studies = 5; I2 = 0%; mod-
erate quality evidence) Analysis 6.3.
Total VTE (symptomatic or asymptomatic)
Therewas significant difference in total VTE in the random-effects
model evaluating four studies favouring DOACs (ADVANCE 3;
RECORD 1 Trial; RE-NOVATE II Trial; RE-NOVATE Trial)
(OR 0.53, 95% CI 0.29 to 0.97; participants = 12,447; I2 = 87%;
moderate quality evidence) Analysis 6.4.
Asymptomatic DVT
In the random-effects model, there was no difference in asymp-
tomaticDVTbetween treatment groups in the two reporting stud-
ies (ADVANCE 3; RE-NOVATE Trial) (OR 0.56, 95% CI 0.19
to 1.59; participants = 6559; I2 = 92%; low quality evidence)
Analysis 6.5.
Asymptomatic proximal DVT
Only a single study (RE-NOVATE Trial) reported on asymp-
tomatic proximal DVT (OR 0.73, 95% CI 0.46 to 1.15; partici-
pants = 2704; moderate quality evidence) Analysis 6.6.
Asymptomatic distal DVT
As for asymptomatic proximal DVT, a single study (RE-NOVATE
Trial) reported on asymptomatic distal DVT (OR 1.22, 95% CI
0.75 to 1.99; participants = 2639; moderate quality evidence)
Analysis 6.7.
All-cause mortality
For the five reporting studies (ADVANCE 3; EXTEND Study;
RECORD 1 Trial; RE-NOVATE II Trial; RE-NOVATE Trial),
there was no difference in all-cause mortality between the treat-
ment groups based on the fixed-effect model ((OR 1.63, 95% CI
0.64 to 4.16; participants = 14,966; studies = 5; I2 = 0%; moderate
quality evidence) Analysis 6.8. Regarding sensitivity analysis, the
RECORD 1 Trial was found to account for 56% of the partici-
pants within this outcome, but after its removal no difference was
seen in the findings.
Adverse events
There was also no difference in adverse events between treatment
groups in the three studies reporting adverse events (RECORD 1
Trial; RE-NOVATE II Trial; RE-NOVATETrial) (OR 0.96, 95%
CI 0.88 to 1.05; participants = 9908; studies = 3; I2 = 0%; high
quality evidence) Analysis 6.9. Regarding sensitivity analysis, the
RECORD 1 Trial was found to account for 50.8% of the partici-
pants within this outcome, but after its removal no difference was
seen in the findings.
Bleeding events (major, clinically relevant non-major, minor)
Major bleeding was reported in five studies (ADVANCE 3;
EXTEND Study; RECORD 1 Trial; RE-NOVATE II Trial;
RE-NOVATE Trial), clinically relevant non-major bleeding was
reported in four studies (ADVANCE 3; RECORD 1 Trial;
RE-NOVATE II Trial; RE-NOVATE Trial), and minor bleeding
was reported in four studies (ADVANCE 3; EXTEND Study;
RE-NOVATE II Trial; RE-NOVATE Trial).
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There were no differences in any of the bleeding event categories
within the studies reporting on bleeding events; major bleeding,
OR 1.11, 95%CI 0.79 to 1.54; participants = 16,199; studies = 5;
I2 = 21%, high quality evidence Analysis 6.10; clinically relevant
bleeding OR 1.08, 95% CI 0.90 to 1.28; participants = 15,241;
studies = 4; I2 = 7%, high quality evidence) Analysis 6.11; minor
bleeding OR 0.95, 95% CI 0.82 to 1.10; participants = 11,766;
studies = 4; I2 = 0%, high quality evidence Analysis 6.12.
For minor bleeding, ADVANCE 3 accounted for 53.3% of the
participants, and when removed in a sensitivity analysis there were
no differences in the association.
Reoperation
Four studies reported on reoperation relating to bleeding (
ADVANCE 3; RECORD 1 Trial; RE-NOVATE II Trial; RE-
NOVATE Trial) showing no differences between the study arms
(OR 1.06, 95% CI 0.34 to 3.24; participants = 15241; studies =
4; I2 = 0%; moderate quality evidence) Analysis 6.13.
The RE-NOVATE Trial accounted for > 50 % of the weight and
when removed in a sensitivity analysis there were no differences in
the association.
Wound infection
Three studies reported on wound infection (RECORD 1 Trial;
RE-NOVATE II Trial; RE-NOVATE Trial). The RE-NOVATE
Trial reported one participant who died of septicaemia and GI
bleeding following ischaemic bowel resection but reported no
other cases of wound infection. Pooling RECORD 1 Trial and
RE-NOVATE II Trial showed no differences in wound infections
between the treatment arms (OR 0.89, 95% CI 0.46 to 1.72; par-
ticipants = 6446; studies = 2; I2 = 0%; moderate quality evidence)
Analysis 6.14.
Wound healing
None of the five studies included in this comparison reported on
wound healing (ADVANCE 3; EXTEND Study; RECORD 1
Trial; RE-NOVATE II Trial; RE-NOVATE Trial).
Reporting bias, subgroup and sensitivity analysis
We did not construct funnel plots for meta analyses because the
meta analyses did not include at least 10 studies.
We planned to apply subgroup analysis to examine participants
undergoing revisions of a previous hip or knee replacement or hip
fracture repair, but we unfortunately found this to be impossible
because these data were not reported separately. As the duration
of the in-hospital/initial phase ranged from four days to 14 days,
subgroup analysis for 15 days or more was not required. Results of
the other planned subgroup analyses are reported above. We did
not consider any studies to be of low quality based on the ’Risk
of bias’ tool and therefore did not perform the planned sensitivity
analysis for this reason.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: vitamin K antagonists
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with vitamin K an-
tagonists
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.10
(0.01 to 1.94)
360
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
23 per 1000 2 per 1000
(0 to 43)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.13
(0.01 to 2.62)
360
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
17 per 1000 2 per 1000
(0 to 43)
Symptomatic PE
Treatment durat ion 28 -
42 days
Study populat ion OR 0.32
(0.01 to 7.84)
360
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
6 per 1000 2 per 1000
(0 to 43)
Bleeding - major
Treatment durat ion 28 -
42 days
see comment OR 2.89
(0.12 to 71.31)
360
(1 RCT)
⊕⊕©©
LOW 12
no events recorded in
placebo group
Clinically relevant non-
major bleeding
Treatment durat ion 28 -
42 days
see comment - - - not reported
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Minor bleeding
Treatment durat ion 28 -
42 days
see comment - - - not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level, results f rom a single study only so heterogeneity could not be assessed
2 Downgraded by one level, number of events small leading to wide CI and imprecision of results
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DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: DOAC
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with DOAC
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.20
(0.06 to 0.68)
2419
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
12 per 1000 3 per 1000
(1 to 8)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.18
(0.04 to 0.81)
2459
(2 RCTs)
⊕⊕⊕⊕
HIGH
-
9 per 1000 2 per 1000
(0 to 7)
Symptomatic PE
Treatment durat ion 28 -
42 days
Study populat ion OR 0.25
(0.03 to 2.25)
1733
(1 RCT)
⊕⊕©©
LOW 12
-
5 per 1000 1 per 1000
(0 to 10)
Bleeding - major
Treatment durat ion 28 -
42 days
Study populat ion OR 1.00
(0.06 to 16.02)
2457
(1 RCT)
⊕⊕©©
LOW 12
-
1 per 1000 1 per 1000
(0 to 13)
Bleeding- clinically rele-
vant non-major
Treatment durat ion 28 -
42 days
Study populat ion OR 1.22
(0.76 to 1.95)
2457
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
2
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27 per 1000 33 per 1000
(21 to 51)
Bleeding - minor
Treatment durat ion 28 -
42 days
Study populat ion OR 1.18
(0.74 to 1.88)
2457
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
28 per 1000 32 per 1000
(21 to 51)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DOAC: direct oral ant icoagulant; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level, results f rom a single study so heterogeneity cannot be assessed
2 Downgraded by one level, low number of events leading to wide CI and imprecision of results
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Anticoagulants (chosen at investigators’ discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: ant icoagulant (chosen at invest igators’ discret ion)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with anticoagulant
(chosen at investiga-
tors’ discretion)
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.50
(0.09 to 2.74)
557
(1 RCT)
⊕⊕©©
LOW 12
-
14 per 1000 7 per 1000
(1 to 38)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.33
(0.03 to 3.21)
557
(1 RCT)
⊕⊕©©
LOW 12
-
11 per 1000 4 per 1000
(0 to 34)
Symptomatic PE
Treatment durat ion 28 -
42 days
Study populat ion OR 1.00
(0.06 to 16.13)
557
(1 RCT)
⊕⊕©©
LOW 12
-
4 per 1000 4 per 1000
(0 to 55)
Bleeding - major
Treatment durat ion 28 -
42 days
see comment OR 5.05
(0.24 to 105.76)
557
(1 RCT)
⊕⊕©©
LOW 12
no major bleeding
recorded in the placebo
groups
2
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Clinically relevant non-
major bleeding
Treatment durat ion 28 -
42 days
see comment - - - not reported
Minor bleeding
Treatment durat ion 28 -
42 days
see comment - - - not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level, results f rom a single study so heterogeneity could not be assessed
2 Downgraded by one level, low number of events leading to wide CIs and imprecision of results
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Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: vitamin K antagonists
Comparison: heparin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with heparin Risk with vitamin K an-
tagonists
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 1.64
(0.85 to 3.16)
1279
(1 RCT)
⊕⊕©©
LOW 12
-
23 per 1000 38 per 1000
(20 to 70)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 1.36
(0.69 to 2.68)
1279
(1 RCT)
⊕⊕©©
LOW 12
-
23 per 1000 31 per 1000
(16 to 60)
Symptomatic PE
Treatment durat ion 28 -
42 days
see comment OR 9.16
(0.49 to 170.42)
1279
(1 RCT)
⊕⊕©©
LOW 13
no cases of symp-
tomatic PE reported in
the heparin study arm
Bleeding - major
Treatment durat ion 28 -
42 days
Study populat ion OR 3.87
(1.91 to 7.85)
1272
(1 RCT)
⊕⊕©©
LOW 12
-
16 per 1000 58 per 1000
(30 to 111)
Bleeding - clinically in-
dicated non-major
Treatment durat ion 28 -
42 days
see comment - - - clinically indicated non-
major bleeding events
not reported in single
included study in this
2
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comparison
Bleeding - minor
Treatment durat ion 28 -
42 days
Study populat ion OR 1.33
(0.64 to 2.76)
1279
(1 RCT)
⊕⊕©©
LOW 12
-
20 per 1000 27 per 1000
(13 to 54)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VKA: vitamin K antagonist ; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level, single study so heterogeneity could not be assessed
2 Downgraded by one level, wide CI
3 Downgraded by one level, low number of events leading to imprecision of results
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DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevent ion of venous thromboembolism following total hip or knee replacement or hip f racture repair
Setting: hospital and outpat ient sett ing
Intervention: DOAC
Comparison: heparin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with heparin Risk with DOAC
Symptomatic VTE (DVT
and PE)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.70
(0.28 to 1.70)
15977
(5 RCTs)
⊕⊕©©
LOW 12
-
4 per 1000 3 per 1000
(1 to 8)
Symptomatic DVT
(proximal or distal)
Treatment durat ion 28 -
42 days
Study populat ion OR 0.60
(0.11 to 3.27)
15977
(5 RCTs)
⊕⊕©©
LOW 23
-
3 per 1000 2 per 1000
(0 to 9)
Symptomatic PE
Treatment durat ion 28 -
42 days
Study populat ion OR 0.91
(0.43 to 1.94)
14731
(5 RCTs)
⊕⊕⊕©
MODERATE 2
-
2 per 1000 2 per 1000
(1 to 4)
Bleeding - major
Treatment durat ion 28 -
42 days
Study populat ion OR 1.11
(0.79 to 1.54)
16199
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
8 per 1000 9 per 1000
(7 to 13)
Bleeding - clinically rel-
evant, non-major
Treatment durat ion 28 -
42 days
Study populat ion OR 1.08
(0.90 to 1.28)
15241
(4 RCTs)
⊕⊕⊕⊕
HIGH
-
3
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33 per 1000 36 per 1000
(30 to 42)
Bleeding - minor
Treatment durat ion 28 -
42 days
Study populat ion OR 0.95
(0.82 to 1.10)
11766
(4 RCTs)
⊕⊕⊕⊕
HIGH
-
66 per 1000 63 per 1000
(55 to 72)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; DOAC: direct oral ant icoagulant; DVT: deep vein thrombosis; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for inconsistency (heterogeneity, I2 = 55%)
2 Downgraded by one level for imprecision due to low number of events leading to wide CI
3 Downgraded by one level for inconsistency (heterogeneity, I2 = 65%)
3
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D I S C U S S I O N
Summary of main results
We have shown that extended-duration prophylaxis with DOACs
in patients undergoing major hip or knee replacement surgery
significantly reduces the risk of symptomatic VTE. This benefit
is achieved with no excess adverse events or major bleeding but
with increased minor bleeding. A significant reduction in PE or
mortality could not be shown but the direction of the treatment
effect for these outcomes was consistent with that seen for the
primary outcome, suggesting that a similar reduction for these
outcomes might be expected.
Our findings of a significant treatment benefit of extended-dura-
tion prophylaxis for prevention of symptomatic VTE are based on
a pooled analysis of both hip and knee replacement trials. How-
ever, our meta-analysis cannot draw a fully informed conclusion
for participants undergoing knee replacement as far fewer studies
evaluated these types of participants separately, as compared with
hip replacement.
When comparing extended-duration anticoagulants (DOACs and
VKA) versus extended-duration LMWHs there were no differ-
ences between the treatments in symptomatic and asymptomatic
VTE and showed decreased odds in total VTE for DOACs versus
LMWH. There was also no difference in mortality, adverse events
or bleeding events. These findings support the use of less invasive
oral anticoagulants versus the more invasive LMWHs which of-
ten have to be administered by injection into subcutaneous tissue.
However, it needs to be kept in mind that several of the meta-
analyses were underpowered and showed heterogeneity. We hope
with the inclusion of new studies in future updates of this review
we will be better able to draw stronger conclusions regarding these
treatment comparisons.
One widely recognised impediment to themore widespread use of
effective prophylaxis in patients undergoing hip or knee replace-
ment is concern about the risk of bleeding. In this regard, the data
from our review are reassuring in that, even with sustained use for
up to six weeks, prophylactic-dose anticoagulants is not associated
with an excess in major bleeding in all comparisons except for the
comparison of VKA versus heparin.
Overall completeness and applicability of
evidence
This review included a total of 16 studies with nearly 25,000
randomised participants. Despite this large number of included
studies some comparisons included a single study only, or few
events were recorded, which led to wide confidence intervals, and
difficulties interpreting the data.
There are other antithrombotic therapies besides the ones eval-
uated in this review that might be used for prevention of VTE
in major orthopaedic surgery or out-of-hospital prophylaxis, for
example aspirin, which were not addressed in this review. We plan
to include these in future updates of this review.
Although compliance with extended-duration prophylaxis seemed
to be 90% or higher in most trials included in our meta-analyses,
the definition of compliance varied among the studies and not all
studies reported the level of compliance with randomised treat-
ment allocation that was achieved. However, the probable impact
of lack of compliance is to reduce the power of a randomised trial
to detect a significant treatment benefit. Therefore an even greater
benefit of extended-duration prophylaxis might be realised in pop-
ulations in which higher levels of compliance are achieved.
Wang 2014 reported that surgical site infections and reoperations
in the three months following joint replacements may be associ-
ated with anticoagulant use and this may be a barrier to extended
thromboprophylaxis but our meta-analyses are underpowered to
draw conclusions on this issue due to a lack of reporting of wound
infections, wound healing and reoperations in the studies included
in this review.
Quality of the evidence
Despite examining the totality of the evidence by pooling results
from all the available properly randomised trials, the total num-
ber of participants randomly assigned and the number of out-
come events was modest. Therefore, our meta-analyses potentially
lacked statistical power to provide precise estimates of frequency
and treatment effect for clinically important outcomes such as
PE. However, DVT and PE represent clinical manifestations of
the same underlying disease process. Therefore, strategies that are
effective for the prevention of DVT, especially those proximally
located, are likely also to be effective for the prevention of non-
fatal and fatal PE.
There was a lot of variation in the design of studies included in our
meta-analyses. However, differences among trials are inevitable
since individual trials look at different populations with different
treatment protocols, and there is always some heterogeneity, even
within individual trials (Lau 1998; Thompson 1994). Differences
in trial design do not necessarily preclude pooling of their results
since, in a meta-analysis, individual participants are directly com-
pared only with other participants within the same trial, and not
across the trials. The validity of our approach is further supported
by the external consistency of our findings with the results of in-
dividual trials.
The quality of the evidence varied by comparison and was on av-
erage moderate. Heterogeneity was found between studies com-
paring DOAC and heparin, and for some outcomes, such as PE
and mortality, few events were recorded during the study peri-
ods leading to imprecision. For three comparisons, only one study
was identified. See Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
32Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair (Review)
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findings 4; Summary of findings 5; Summary of findings 6 for
further details.
Potential biases in the review process
Every effort was made to limit potential biases in the review
through duplication of study selection, data extraction and assess-
ment of risk of bias by two review authors. Also, we utilised pre-
designed data extraction forms and discussed any disagreements
and undertook a meticulous and exhaustive search for both pub-
lished and unpublished studies.
Despite these techniques to reduce bias, there are still areas of con-
cern. One issue was with the total numbers of participants used in
themeta-analyses. Most of the included studies had large numbers
of participants that were excluded after randomisation. This was
due mainly to detecting DVT at discharge from the hospital, non-
compliance, adverse events and non-evaluable objective testing of
DVT. Due to these large numbers of exclusions it was inappropri-
ate to use all randomised participants, and we therefore attempted
to use the most reliable intention-to-treat population as reported
by the study authors. This method required us to adapt the num-
bers used by the study authors, which did vary between studies.
We did not stratify according to the use of mechanical prophylaxis
since, inmost studies, the use of mechanical prophylaxis was left to
the discretion of the local investigator and is usually not reported
separately in the final study report. However, this should not lead
to any bias because the use of mechanical methods is likely to
be balanced between the two groups as a result of proper use of
randomisation.
Agreements and disagreements with other
studies or reviews
A recently published meta-analysis evaluated extended duration
using new oral anticoagulants versus extended duration using
LMWHs (Liew 2014). The four included studies are also included
in our review. For symptomatic VTE they found a risk ratio in
favour of oral anticoagulants of 0.42 (95% CI 0.21 to 0.86). Al-
though Liew 2014 included RE-NOVATE Trial in their review,
they did not include this study in the evaluation of symptomatic
VTE, which led to the major differences in our findings, as the
two dabigatran treatment groups had a large number of VTEs,
compared with the LMWHgroup. Liew 2014 also did not include
the SACRE Study. Liew 2014 found no difference in mortality or
bleeding events, which is similar to our own review.
A meta-analysis published in 2001 compared extended-duration
prophylaxis to short duration followed by placebo or no treatment
(Eikelboom 2001). Eikelboom 2001 included nine studies, five
of which were also included in our review and the other four
we excluded because we deemed they did not meet the five-week
treatment-duration requirement for this review. Eikelboom 2001’s
findingswere similar to ours, with a decreased odds of symptomatic
DVT in the extended duration treatment group (OR 0.38, 95%
CI 0.24 to 0.61), no difference in major bleeding but an increase
in minor bleeding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Extended-duration thromboprophylaxis should be considered for
people undergoing hip or knee replacement, but the risk of in-
creased minor bleeding should be carefully considered.
Implications for research
Continued research in this area is needed, specifically as newer,
and possibly safer medications become available. Oral anticoag-
ulants could be a promising alternative to LMWHs that require
daily injections, but the evidence is currently insufficient. Specif-
ically, further research is required to better understand the asso-
ciation between VTE and extended-duration oral anticoagulants
in relation to knee replacement and hip fracture repair as well as
outcomes such as distal and proximal DVT, reoperation, wound
infection and healing, regarding the optimal duration of extended
therapy, possibility of combining therapies and effects of extended
therapies on length of hospital stay. An assessment of cost-effec-
tiveness as part of the further research is also warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ADVANCE 3
Methods Study design: Randomised, double-blind, double-dummy, clinical trial
Country:Multi-Country (21)
Setting: Multicentre (160 sites); home and hospital; March 2007 to May 2009
Intention-to-treat: Yes, primary analysis on all except those that had no or venograms
or uninterpretable venography, also per-protocol efficacy analysis excluding protocol
violations - protocol violations not described - safety data ITT minus those that did not
receive at least one dose
For the purposes of our meta-analyses we used a mixture of all randomised and ITT
population, as reported appropriate by the study authors
Participants Number randomised: Total n = 5407 (apixaban n = 2708; enoxaparin n = 2699)
Exclusions post randomisation: Total n = 1616 (Apixaban: 363 had no venography,
396 had uninterpretable venograms (efficacy), 35 did not have at least one dose (safety)
. Enoxaparin: 40 did not receive at least one dose (safety); 364 no venography, 418
uninterpretable venogram (efficacy))
Losses to follow up: No reports of loss to follow up
Age mean (range): Apixaban 60.9 (19 - 92); enoxaparin 60.6 (19 - 93)
Sex (%F): Apixaban 52.8%; enoxaparin 53.8%
Inclusion criteria: Patients scheduled to undergo elective total hip replacement or revi-
sion of previously inserted hip replacement
Exclusion criteria: Main reasons for exclusion: active bleeding; contraindication to
anticoagulant prophylaxis; need for ongoing anticoagulant or antiplatelet treatment
Interventions Treatment: 2.5 mg apixaban, orally, twice daily, initiated 12 - 24 hours after surgery
Control: 40mg enoxaparin, subcutaneously, once daily, initiated 12 hours before surgery
Duration: Prophylaxis continued for 35 days (32 to 38 day range) after surgery; follow-
up evaluations also occurred at 65 and 95 days after surgery
Outcomes Primary:Composite of asymptomatic or symptomatic DVT, nonfatal PE, or death from
any cause; bleeding during treatment period (classed as major, clinically relevant non-
major and minor bleeding, and composite of major and clinically relevant)
Secondary: Major VTE: composite of symptomatic or asymptomatic proximal DVT,
nonfatal PE or death related to VTE
Bleeding definitions: Major bleeding - acute, clinically overt bleeding accompanied by
one or more of the following: a decrease in haemoglobin level of 2 g/dL or more over 24
hours; transfusion of 2 or more units of packed red cells; bleeding into the operated joint
necessitating reoperation or intervention; intramuscular bleeding; fatal bleeding;Minor
bleeding - clinically overt but did not meet the criteria for major or clinically relevant
non-major bleeding; Clinically relevant non-major bleeding - acute, clinically overt
episodes such as wound haematoma, bruising or ecchymosis, gastrointestinal bleeding,
haemoptysis, haematuria or epistaxis that did not meet the criteria for major bleeding
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ADVANCE 3 (Continued)
Notes Funding: Bristol-Myers Squibb and Pfizer
Method of VTE evaluation/confirmation: bilateral venography was performed after
35 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using interactive telephone
system, randomisation schedule generated
at the randomisation centre of Bristol-My-
ers Squib with the use of SAS software and
was stratified according to study site, with
a block size of four
Allocation concealment (selection bias) Low risk Interactive telephone system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as
double-blind, double-dummy, participants
received either placebo tablets or injections
based on treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All VTE, bleeding and adverse events were
reviewed by an independent, blinded, ad-
judication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All losses-to-follow-up were recorded per
treatment group with adequate reasoning
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Unclear risk Reasons for protocol violations not de-
scribed; Funded by Bristol-Myers Squibb
and Pfizer; data were collected and moni-
tored by the sponsors, and data and safety
monitoring board were given a fee by the
sponsors
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Barrellier 2010
Methods Study design: Randomised, open-label, prospective, non-inferiority, parallel group trial
Country: France
Setting: Multicentre (17 centres); hospital and home; June 2004 to June 2007
Intention-to-treat: No
For the purposes of our meta-analyses we used the per-protocol population, as reported
by the study authors
Participants Number randomised: Total n = 857 (extended n = 430; short n = 427)*
Exclusions post randomisation: Extended: exclusion criteria: 7, not treated: 13; short:
exclusion criteria 2, consent withdrawal 4 not treated: 33
Losses to follow up: Extended n = 1; short n = 1
Age mean years (SD): Extended 70.9 (8.1); short 70.1 (8.6)
Sex % M: Extended 37.9%; short 35.4%
Inclusion criteria:45years or older; scheduled for a first total unilateral knee arthroplasty
Exclusion criteria:History of confirmed symptomatic venous thromboembolism at any
time, stroke or myocardial infarction within the previous month, current active bleed,
gastrointestinal bleeding or hemorrhagic stroke within the previous six months, brain,
spinal, opthalmological or other major surgery within the previous month, active can-
cer, renal impairment, hepatic impairment, a contraindication to anticoagulant therapy,
hypersensitivity to heparin and patients who required therapeutic anticoagulation
Interventions Treatment: Anticoagulant treatment was chosen by the investigator and could be: hep-
arin (5000 U, two to three times per day), enoxaparin (4000 IU), dalteparin (5000 IU)
, tinzaparin (4500 IU), body-weight adjusted nadroparin, fondaparinux (2.5 mg)
Control:No specific control, only short duration prophylaxis
Duration: 10 ± 2 days ’short thromboprophylaxis’; 35 ± 5 days ’extended thrombopro-
phylaxis’
Outcomes Primary: Composite of proximal DVT, symptomatic DVT, non-fatal symptomatic PE,
major bleeding, heparin-induced thrombocytopenia, all-cause mortality
Secondary: Ultrasonographic distal DVT
Bleeding definitions: Major bleeding fatal bleeding, bleeding that was intracranial,
intraocular, retroperitoneal, gastrointestinal or intra-articular, bleeding leading to reop-
eration, or bleeding requiring cessation of treatment
Notes Funding: Caen University Hospital with unrestricted grant from the French Health
Ministry
Method of VTE evaluation/confirmation: All participants were examined for DVT by
bilateral whole-leg ultrasonography on Day 35 ± 5, or earlier if thrombosis was clinically
suspected
*For the analysis, we only included participants that had negative ultrasonographic scans
at discharge, as most comparative studies excluded these participants with positive ul-
trasonographic scans at discharge
Risk of bias
Bias Authors’ judgement Support for judgement
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Barrellier 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Concealed randomisation was performed
using a centralised telephone system, ac-
cording to a permuted block design with
block size of four, with stratification by cen-
tre and by the presence or absence of distal
deep-vein thrombosis on whole leg ultra-
sonography
Allocation concealment (selection bias) Low risk “Concealed randomization was performed
using a centralized telephone system”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Sonographer was not blinded; Primary out-
comes were reviewed by a central, indepen-
dent, blinded adjudication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) High risk Safety outcomes reported as “the bleeding
riskwas very low (0.7%)”, no further details
provided
Other bias Low risk Sponsored by theCaenUniversityHospital
with an unrestricted grant from the French
Health Ministry - which had no other role
in the study
Dahl 1997
Methods Study design: Randomised, prospective, double-blind, placebo-controlled trial
Country: Norway
Setting: Multicentre, hospital and home, January 1993 - June 1994
Intention-to-treat: Yes, after withdrawals removed.
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 265 (extended LMWH n = 134; placebo n = 131)
Exclusions post randomisation: Total n = 38 (extended LMWH n = 17; placebo n
= 21) withdrawn for reasons other than DVT or PE (21/38 due to adverse events: 10
extended LMWH and 11 placebo)
Losses to follow up:No losses to follow-up all participants received treatment until the
day of final visit
Age mean years: Extended LMWH 70.98, placebo 71.4
Sex %F: Extended LMWH 68.5%; placebo 73.6%
Inclusion criteria: 18 years or older; admitted to hospital for elective primary or sec-
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Dahl 1997 (Continued)
ondary hip replacement; obtained written consent form
Exclusion criteria: Known renal or liver insufficiency; cerebral bleeding less than three
months before surgery or known haemorrhagic diathesis; eye or ear surgery within one
month before surgery; severe hypertension; septic endocarditis; threatened arterial cir-
culation in the leg; body weight less than 40 kg; anticoagulant therapy less than one
week before surgery; known hypersensitivity to heparin, low-molecular-weight heparin,
dextran or contrast media; pregnancy or breastfeeding; inability to comply with study
protocol; previous surgery within study
Interventions Treatment: Dalteparin 5000 IU, injections once daily for four weeks
Control: Initial treatment with dalteparin 5000 IU followed by placebo (sodium chlo-
ride) injections, once daily
Duration: 35 days (7 days initial treatment + 28 days continued treatment)
Outcomes Primary: Verified VTE on days 7 and 35
Secondary: Haematological assessment; safety: reoperation due to bleeding, wound
haematoma and local haematoma at injection site
Notes Funding: Not reported
Method of VTE evaluation/confirmation: DVT verified by bilateral venography and
PE verified by perfusion ventilation or chest X-ray
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information given to deter-
mine adequate randomisation
Allocation concealment (selection bias) Unclear risk Insufficient information given to deter-
mine adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blinded and gave
placebo subcutaneous injections
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Venograms, X-rays and V-Q scans evalu-
ated after the study by a blinded specialist
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, ITT and PP
analysis
Selective reporting (reporting bias) High risk VAS patient acceptability reported but not
reported as pre-planned, as was pain at
injection site and serious adverse events,
bleeding not reported as outcomes
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Dahl 1997 (Continued)
Other bias Low risk No evidence of other bias
DaPP Study
Methods Study design: Randomised, double-blind, placebo-controlled, parallel group, prospec-
tive trial
Country: Denmark
Setting: Multicentre; hospital and home; January to November 1994
Intention-to-treat: Yes
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 281 (extended LMWH n = 140; placebo n = 141)
Exclusions post randomisation: Total n = 66 (extended LMWH n = 27; placebo n =
39);
39 due to inadequate or missing phlebographies, 14 withdrew consent, 8 adverse events,
2 placebo patients with symptoms of PE had inconclusive lung scans, 2 withdrawn due
to reoperation and 1 used other anticoagulant drug
Losses to follow up: Not reported
Age median years (range): Extended LMWH 68 (30 - 94); placebo 70 (28 - 91)
Sex M/F: Extended LMWH 66/74; placebo 62/79
Inclusion criteria: All participants admitted for total hip replacement; age 18 years or
older
Exclusion criteria: Previous surgery in the study; simultaneous participation in another
pharmacological study; informed consent not obtained; high probability for drop-out;
renal insufficiency; hepatic insufficiency; prothrombin < 0.7; platelet count < 100 x 10
9/L; treatment with oral anticoagulants or heparin within seven days before inclusion;
hypersensitivity to heparin, LMWH or contrast media; documented bleeding within
threemonths prior to surgery; intracranial bleeding within threemonths prior to surgery;
eye, ear or CNS surgery within one month prior to surgery; hypertension with diastolic
pressure > 120 mmHg; septic endocarditis; body weight < 40 kg; known pregnancy or
lactation
Interventions Treatment: Dalteparin subcutaneous injections (5000 anti-Xa), once daily
Control: Initial treatment with dalteparin (5000 anti-Xa) followed by placebo (sodium
chloride) injections, once daily placebo subcutaneous injections, once daily, started after
discharge
Duration: 35 days after surgery
Outcomes Primary: DVT and PE
Secondary: Bleeding complications and adverse events; haemological analysis
Bleeding definitions: No definition for major bleeding was provided
Notes Funding: Not reported
Method of VTE evaluation/confirmation: Bilateral ascending phlebography at the end
of treatment to detectDVT; PEdetected by perfusion/ventilation lung scanor pulmonary
angiography
Risk of bias
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DaPP Study (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed with a sep-
arate randomisation list for each centre
Allocation concealment (selection bias) Unclear risk Insufficient information given to deter-
mine adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo injections, saline, given to control
participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All venograms were evaluated by a panel of
three radiologists who were unaware of the
result of the randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, similar
numbers in groups, no missing outcome
data
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
EXTEND Study
Methods Study design: Randomised, double-blind, parallel-group study
Country:Multi-country (16 countries)
Setting: Multicentre; hospital and home; September 2005 to February 2006
Intention-to-treat: No analysis performed as study stopped prematurely
For the purposes of our meta-analyses we used the per-protocol population as reported
by the authors
Participants Number randomised: Total n = 1158; 641 completed at time of termination (ximela-
gatran n = 580; enoxaparin n = 578)
Exclusions post randomisation: Total n = 150 (ximelagatran n = 70; enoxaparin n =
80)
Not treated: 23 melagatran, 16 enoxaparin;
Premature stop: 47 melagatran, 64 enoxaparin
Losses to follow up: Study terminated early
Age median years (range): Hip replacement: ximelagatran 64.7 (24 - 89); enoxaparin
63.9 (21 - 89); Fracture surgery: ximelagatran 73.1 (44 - 91); enoxaparin 70.7 (26 - 94)
Sex M/F: Hip replacement: ximelagatran 229/250; enoxaparin 211/268; Fracture
surgery: Ximelagatran 17/60; enoxaparin 23/50
Inclusion criteria: 18 years or older; undergoing primary elective unilateral total hip
replacement or surgery for hip fracture
Exclusion criteria: “same as in the previously reported phase III studies in orthopaedic
surgery on ximelagatran”
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EXTEND Study (Continued)
Interventions Treatment 1: 3 mg ximelagatran subcutaneously 4 - 8 hours after surgery and twice daily
for up to 2 days post-op, followed by 24 mg oral ximelagatran twice daily
Treatment 2:40mgenoxaparin subcutaneous once daily starting the night before surgery
or post-operatively
Duration: 32 - 38 days after surgery; Randomised within 5 days before surgery
Outcomes Primary: Efficacy outcomes: composite of proximal DVT, any clinically suspected and
objectively confirmed DVT and/or PE, VTE-related death or death where VTE could
not be ruled out. Safety outcomes: major bleeding events, transfusions of whole blood
and packed red blood cells, injection site haematomas > 2 cm, clinically verified and
adjudicated myocardial infarction, evidence of hepatic injury
Secondary: No distinction between primary and secondary
Bleeding definitions: Major bleeding - transfusions of whole blood and packed red
blood cells, injection site haematomas > 2 cm, clinically verified and adjudicated my-
ocardial infarction, evidence of hepatic injury
Notes Funding: AstraZeneca, Sweden; employees of AstraZeneca contributed to study design,
interpretation of results and decision to submit paper
Method of VTE evaluation/confirmation: bilateral compression ultrasound (CUS) of
the legs at the end of treatment period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive web-based randomisation sys-
tem; stratified by type of surgery
Allocation concealment (selection bias) Low risk Used web-based randomisation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes adjudicated by a blinded, inde-
pendent committee
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT numbers do not add up; insufficient
information given
Selective reporting (reporting bias) Unclear risk Nodetails of the VTE events were provided
Other bias High risk Terminated early due to safety issues, As-
traZeneca supported trial - had influence
on study design, interpretation of results
and decision to submit paper
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Fragmin Trial
Methods Study design: Randomised, double-blind, clinical trial
Country: USA and Canada
Setting: Multicentre (18 centres); hospital and home
Intention-to-treat:Yes, ITT:VTEanalysis performedonparticipantswhohad successful
venography, safety analysis with those who had successful venogram at day six
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 991 but only n = 569 received treatment (pre-op
dalteparin n = 199; post-op dalteparin n = 190; warfarin/placebo n = 180)
Exclusions post randomisation: Total n = 293: 94 refused participation, 40 adverse
event in-hospital, 12 unable to self inject, 42 other reasons, plus 105 no or inadequate
venography
Losses to follow up: No reports of losses to follow up but could be part of 42 other
reasons for no venography
Age mean years (SD): Pre-op dalteparin 62 (12); post-op dalteparin 63 (12); warfarin/
placebo 63 (12)
Sex M/F: Pre-op dalteparin 106/93; post-op dalteparin 87/103; warfarin/placebo 94/86
Inclusion criteria: Aged 18 years or older; scheduled for elective unilateral total hip
replacement; gave informed consent
Exclusion criteria: Documented bleeding within three months before surgery; known
hypersensitivity to heparin, LMWH, warfarin or contrast media; defective haemostasis;
ongoing anticoagulant therapy; pregnancy or breastfeeding; clinically significant hep-
atic dysfunction; renal insufficiency; severe hypertension; septic endocarditis; weight less
than 40 kg; eye, ear or central nervous system surgery within one month before hip
surgery; diseases with unfavourable prognosis or concurrent disease making study par-
ticipation medically complicated; simultaneous participant in another study or receiving
any investigation drug 30 days or less before surgery; previous randomisation into this
study; use of pneumatic compression stockings during study period
Interventions Treatment 1: Dalteparin sodium, subcutaneous, 5000 IU once daily, commenced two
hours before surgery plus placebo capsules while in hospital
Treatment 2: Dalteparin sodium, subcutaneous, 5000 IU once daily, commenced four
hours after surgery plus placebo capsules while in hospital
Control: Placebo
Duration: 35 ± 2 days
Outcomes Primary: Venogram-confirmed DVT and proximal DVT
Secondary: PE, bleeding complications, death
Bleeding definitions: Major bleeding - clinically overt, associated with a decrease in
haemoglobin of 20 g/L or more; if it required a blood transfusion of 2 or more units;
intracranial, intraocular, intraspinal or intraperitoneal; occurred into a prosthetic joint
Minor bleeding - clinically overt but not meeting criteria for major
Notes Funding: A grant-in-aid by Pharmacia & Upjohn to the University of Calgary
Method of DVT and PE evaluation/confirmation: Participants with VTE symptoms
received objective testing for confirmation; bilateral ascending venography was per-
formed at discharge and at the end of the study period for all participants
Risk of bias
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Fragmin Trial (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed using com-
puter-derived treatment schedule, divided
into consecutive blocks, stratified by treat-
ment centre
Allocation concealment (selection bias) Low risk Randomisation by computer-derived
methods
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Used placebo dalteparin injections and
placebowarfarin capsules tomaintain blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Venograms were interpreted by a blinded
central reader as well as a local radiologist;
disagreements resolved by a second blinded
interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
French Study
Methods Study design: Randomised, double-blind, placebo controlled trial
Country: France
Setting: Single centre; hospital and home; August 1991 to June 1994
Intention-to-treat:Yes, ITTandper-protocol, although based on secondbilateral venog-
raphy
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 179 (extended LMWH n = 90; placebo n = 89)
Exclusions post randomisation: Total n = 6 (extended LMWH n = 5; placebo n = 1),
had no second venogram and excluded from efficacy analysis
Losses to follow up: No losses to follow up; all participants included in safety analysis
Age mean years (SD): Extended LMWH 70 (9.1); placebo 68 (8.2)
Sex M/F: Extended LMWH 47/43; placebo 55/34
Inclusion criteria:Underwent primary total hip replacement or conversion/reversion of
total hip replacement; received prophylactic treatmentwith enoxaparin for post-opVTE;
> 45 years of age; body weight 45 - 95 kg; could walk unassisted using crutches; were
free of DVT as assessed by bilateral ascending contrast venography performed within
five days before discharge; had to be available for a follow-up visit at day 21 ± 2 days
post discharge
Exclusion criteria: History of documented DVT or PE within last six months; active
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French Study (Continued)
cancer; underlying bleeding disorders or haemostasis abnormalities; prothrombin time <
60% or activated partial thromboplastin time > 8 seconds or longer than control subjects;
active gastroduodenal ulcer; history of hypersensitivity to heparin or to contrast media;
renal or hepatic insufficiency; uncontrolled hypertension; recent stroke; inability to give
informed consent
Interventions Treatment: 40 mg enoxaparin, subcutaneous, daily
Control: 40 mg enoxaparin, subcutaneous, daily during hospitalisation (14 ± 1 day)
followed by placebo (isotonic saline) injections
Duration: 35 days after surgery
Outcomes Primary: DVT and/or PE
Secondary: Onset of proximal or distal DVT; safety: death, major and minor haemor-
rhages, adverse events
Bleeding definitions: Major bleeding - overt and was associated with a decrease in
haemoglobin concentration of 2 g/dL or more compared with the last postoperative
value, or a need for transfusion of two or more units of packed red blood cells, or if it
was retroperitoneal or intracranial. Minor bleeding - overt but did not meet the other
criteria for major bleeding
Notes Funding: Not reported
Method of VTE evaluation/confirmation:Clinical evaluation of symptoms and clinical
signs of DVT and bilateral venographic evaluation at day 35 post-surgery
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was balanced in blocks of
four by means of a computer-generated
randomization schedule.”
Allocation concealment (selection bias) Low risk Used computer-generated randomisation
schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open-label during hospitalisation period
when all patients receiving enoxaparin,
then double-blinded after randomisation
to extended duration or placebo using
saline injections for the placebo group;
“The double-blind conditions (for pa-
tients, nurses, attending physicians, and
investigators) were maintained until the
database was locked.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Venograms were independently evaluated
by two blinded radiologists
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French Study (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
Heit 2000
Methods Study design: Randomised, double-blind, placebo-controlled trial
Country: US
Setting: Multicentre (33 centres); hospital and home; November 1994 to November
1997
Intention-to-treat: Yes
For the purposes of our analyses we used all participants randomised, as reported by the
study authors
Participants Number randomised: Total n = 1195 (Extended LMWH n = 607; Placebo n = 588)
Exclusions post randomisation: Unclear
Losses to follow up: Unclear
Age mean years (SD): Extended LMWH 65 (11); placebo 66 (11)
Sex M/F: Extended LMWH 265/342; placebo 275/313
Inclusion criteria: Aged 18 years or older; received elective primary or revision unilateral
total hip replacement, primary unilateral or bilateral total knee replacement
Exclusion criteria: ’Pregnant, lactating or women of childbearing age; patients with
clinical bleeding disorder; uncontrolled hypertension’ severely impaired hepatic or renal
function; active alcohol or drug abuse; patients who could not comply with home in-
jections or complete a 10-week post-op follow-up; patients receiving warfarin or throm-
bolytic therapy; had a major surgery within previous seven days; had major orthopaedic
surgery involving lower extremities in previous six weeks; history of substantial internal
bleeding, active peptic ulcer, myocardial infarction or stroke; intracranial or intraocular
surgery in previous eight weeks; patients planning to undergo staged bilateral total knee
replacement with anticipated interval of less than 10 weeks; hypersensitivity to heparin,
pork products, metabisulphite, methylparaben or propylparaben; weight great than 120
kg; prolonged activated partial thromboplastin time or prothrombin time at baseline;
baseline platelet count less than 100 x 109/L; history of VTE; current use of dextran
sulphate, desmopressin acetate, other LMWH, oral anticoagulants, thrombolytic agents
or external pneumatic compression
Interventions Treatment: Ardeparin sodium 100 anti-Xa IU/kg weight, subcutaneous injections, daily,
starting within 24 hours after surgery
Control: Four to 10 days ardeparin sodium 100 anti-Xa IU/kg weight (starting within
24 hours after surgery), daily, subcutaneous injection, followed by placebo injections
from time of discharge
Duration: Six weeks after surgery
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Heit 2000 (Continued)
Outcomes Primary: Incidence of symptomatic, objectively documented DVT or PE or death
Secondary: The incidence of major and minor bleeding and thrombocytopenia
Bleeding definitions: Major bleeding - overt bleeding associated with haemoglobin
decrement of at least 20 g/L or transfusion of at least 2 units of blood products, any
intracranial, retroperitoneal, intraocular or mediastinal bleeding that occurred after at
least one dose of post-discharge study drugMinor bleeding - overt bleeding not meeting
the criteria for major bleeding
Notes Funding:Wyeth-Ayerst Research, Philadelphia, US - performed statistical analysis, data
interpretation and manuscript preparation done by writing committee, sponsor did not
have prior right of approval for final manuscript publication
Method of VTE evaluation/confirmation: Compression duplex ultrasonography or
venography, ventilation perfusion lung scanning or pulmonary angiography
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by clinical centre, type of surgery
and history of VTE; block randomisation
derived from a randomisation table
Allocation concealment (selection bias) Low risk Allocation done in consecutively num-
bered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind phase of study achieved by
giving placebo injections in identical Tubex
cartridges containing 0.5 mL ardeparin
sodium or placebo (sodium chloride solu-
tion)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by blinded, central ad-
judication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, although >
15% withdrew in both groups
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
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Kolb 2003
Methods Study design: Randomised, double blind, placebo controlled trial
Country: Germany and Czech Republic
Setting: Multicentre (13 centres), hospital and home
Intention-to-treat: Yes and per-protocol
For the purposes of our analyses we used all participants randomised, as reported by the
study authors
Participants Number randomised: Total n = 310 (extended LMWH n = 161; placebo n = 149)
Exclusions post randomisation: Total n = 37: protocol violation: 8, adverse events:10,
withdrawal of consent: 19
Losses to follow up: None
Age mean years (SD): Extended LMWH 78.1 (8.4); placebo 75.8 (8.4)
Sex M/F: Extended LMWH 25/136; placebo 29/120
Inclusion criteria: Participants undergoing endoprosthetic joint replacement or os-
teosynthesis of the lower limb
Exclusion criteria: Age under 18 years; hypersensitivity against heparin; clinical condi-
tions with increased risk of bleeding; haemorrhagic diathesis; platelet count < 100.000/
ul; concomitant treatment with anticoagulants or platelet inhibitors; renal or hepatic
insufficiency; hypertension with systolic values > 200 mmHg and diastolic values > 105
mmHg despite treatment; malignancy; endocarditis lenta; drug abuse; pregnancy; par-
ticipation in a clinical trial during the last four weeks; thromboembolic complications
between start of treatment and randomisation; discontinuation of study medication due
to adverse events; withdrawal of consent
Interventions Treatment: Certoparin 3000 u anti-Xa
Control: Certoparin 3000 u anti-Xa for 14 days then placebo
Duration: 42 days
Outcomes Primary: Composite of symptomatic or asymptomatic DVT (proximal and/or distal),
symptomatic PE and deaths related to VTE
Secondary: Coagulation parameters
Bleeding definition - not provided
Notes Funding: Supported by Novartis Pharma, Germany, test kits for fibrin monomers and
Ddimer sponsored by Roche Diagnostics Germany, protein C resistance kits sponsored
by Dada Behring Germany
Method of VTE evaluation/confirmation: DVT was screened for by compression and
duplex ultrasonography every week and confirmed by ascending leg and pelvic venog-
raphy (whenever possible). PE was verified by pulmonary angiography, spiral CT or
perfusion lung scanning
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided on se-
quence generation
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Kolb 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information provided on allo-
cation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, participants given placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided on asses-
sor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, although
treatment group was not indicated for loss-
to-follow-ups
Selective reporting (reporting bias) Low risk All defined outcomes were reported on
Other bias Low risk No indication of other bias
Prandoni 2002
Methods Study design: Prospective randomised controlled trial
Country: Italy
Setting: Single centre; hospital and home; September 1998 to December 2000
Intention-to-treat: Yes
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 360 (extended duration n = 184; control n = 176)
Exclusions post randomisation: Total n = 6: three protocol violations per group but all
were available for clinical follow-up
Losses to follow up: None
Age median years (range): Extended duration 68 (48 - 82); control 69 (44 - 87)
Sex M/F: Extended duration 83/101; control 79/97
Inclusion criteria: Underwent elective total hip replacement; received warfarin prophy-
laxis during hospitalisation
Exclusion criteria: Previous hip surgery on the same side; history of thromboembolic
disorder; needing long-term anticoagulation; were unavailable for long-term follow-up;
refused to give written informed consent; developed VTE complications, asymptomatic
proximal DVT or major bleeding during hospitalisation period
Interventions Treatment: 5 mg/d of warfarin sodium prophylaxis starting two days pre-op; dosage
adjusted to increase international normalised ration between 2.0 and 3.0
Control: 5 mg/d of warfarin sodium prophylaxis starting two days pre-op; dosage ad-
justed to increase international normalised ration between 2.0 and 3.0, discontinued at
discharge
Duration: 4 weeks after discharge (Median nine day hospitalisation plus four weeks
extended treatment)
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Prandoni 2002 (Continued)
Outcomes Primary: Composite of symptomatic VTE and asymptomatic proximal DVT during
first four weeks of follow up, efficacy during complete three months follow up, clinical
parameters, also reports on major bleeding, death and other adverse events
Secondary: Not specifically defined
Bleeding definitions: Major bleeding - clinically overt and associated with either a
decrease in haemoglobin of at least 2.0 g/dL or a need of transfusion of two or more units
of blood, was intracranial or retroperitoneal, resulted in permanent discontinuation of
treatment
Notes Funding: Not reported
Method of VTE evaluation/confirmation: compression ultrasonography for DVT; PE
confirmed by ventilation perfusion, spiral CT, abnormal finding on angiography or
autopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Computer-generated list
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No discussion of blinding and no placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Ultrasound was performed by a blinded
operator; cause of death adjudicated by a
blinded physician and all outcomes evalu-
ated by a blinded committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for and no loss
to follow-up
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias High risk Terminated early “after inclusion of the first
360 patients because a statistically signif-
icant and clinically relevant superiority of
extended over short-term thromboprophy-
laxis was observed”
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RE-NOVATE II Trial
Methods Study design: Randomised, double-blind, double-dummy, non-inferiority, active-con-
trolled trial
Country: 19 countries in Europe, North America, India, Australia, New Zealand and
South Africa
Setting: Multicentre (108 locations); hospital and home; March 2008 to May 2009
Intention-to-treat: Modified intention-to-treat: all participants who had surgery, re-
ceived treatment and had evaluable venograms
For the purposes of our meta-analyses we used the reported ITT population of partici-
pants that underwent surgery
Participants Number randomised: Total n = 2055 (dabigatran n = 1036; enoxaparin n = 1019)
Exclusions post randomisation: Total n = 477 (dabigatran n = 243; enoxaparin n =
234: not treated: dabigatran 25 and enoxaparin 16. Dabigatran 9 and enoxaparin 11 did
not have surgery, dabigatran 209 and enoxaparin 207 no or not evaluable venogram
Losses to follow up: All participants accounted for
Age mean years (SD): Dabigatran 62 (12); enoxaparin 62 (11)
Sex F%: Dabigatran 53.6%; enoxaparin 50.0%
Inclusion criteria: 18 years or older; scheduled to undergo a primary, unilateral, elective
total hip replacement; > 40 kg body weight; gave written informed consent
Exclusion criteria: History of bleeding diathesis; excessive risk of bleeding as judged by
investigators; major surgery or trauma within three months of enrolment; recent unsta-
ble cardiovascular disease; any history of haemorrhagic stroke or any of the following
intracranial pathologies: bleeding, neoplasm, atriovenous malformation or aneurysm;
ongoing treatment for VTE; clinical relevant bleeding within six months of enrolment;
gastric or duodenal ulcer within one year of enrolment; liver disease expected to have
any potential impact on survival; active liver disease or liver disease decreasing survival;
known severe renal insufficiency; elevated creatinine that contraindicates venography;
Treatment with anticoagulants, clopidogrel, ticlopidine, abciximab, aspiring or NSAID
within seven days prior to hip replacement or anticipated need of such medication; an-
ticipated required use of intermittent pneumatic compression and electric stimulation
of lower leg; active malignant disease or current cytostatic treatment; pre-menopausal
women who are pregnant or nursing, or are of child-bearing potential and are not prac-
tising or do not plan to continue practising acceptable methods of birth control; allergy
to radio opaque contrast media, heparins or dabigatran; contraindications to enoxaparin;
participation in a clinical trial during the last 30 days; leg amputee; known alcohol or
drug abuse which would interfere with study completion; previous participation in this
study; history of thrombocytopaenia
Interventions Treatment 1: 220 mg dabigatran etexilate (2 x 110 mg tablets), orally, once daily, initial
dose of 110 mg on the day of surgery plus placebo injection identical to enoxaparin
treatment
Treatment 2: 40 mg enoxaparin, subcutaneous, once daily, initial dose evening before
surgery plus placebo tablets identical to dabigatran treatment
Duration: 28 - 35 days
Outcomes Primary: Composite of total VTE and all-cause mortality (VTE includes both proximal
and distal DVT, symptomatic DVT, PE)
Secondary:MajorVTEandVTE-related death, proximalDVT, totalDVT, symptomatic
DVT, PE, all-cause mortality, bleeding events, lab parameters and adverse events
Bleeding definitions: Major bleeding - fatal, clinically overt associated with loss of
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RE-NOVATE II Trial (Continued)
haemoglobin greater than or equal to 20 g/L or leading to transfusion of greater than or
equal to 2 units of packed cells or whole blood; symptomatic retroperitoneal, intracra-
nial, intraocular or intraspinal; requiring treatment cessation; leading to reoperation.
Clinically relevant bleeding - spontaneous skin haematoma greater than or equal to
25 cm2; wound haematoma greater than or equal to 100 cm2; spontaneous nose bleed
lasting longer than 5min; macroscopic haematuria spontaneous or lasting longer than 24
hours if associated with an intervention; spontaneous rectal bleeding (more than a spot
on toilet paper); gingival bleeding lasting longer than 5 min; any other bleeding event
considered clinically relevant by the investigator Minor bleeding - any other bleeding
events that were not classified as major or clinically relevant
Notes Funding: Boehringer Ingelheim, Sweden
Method of VTE evaluation/confirmation: DVT confirmed/detected by bilateral
venography or compression ultrasound or autopsy; PE confirmed by pulmonary V-Q
scintigraphy, chest X-ray, angiography, spiral CT or autopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by central computer-gen-
erated system, stratified by centre, prepared
in blocks of six
Allocation concealment (selection bias) Low risk Utilised central computer-generated sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both treatment groups received one study
drug and one placebo identical in appear-
ance to the other active treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Efficacy outcomes confirmed by blinded,
central adjudication committee
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants were accounted for, with
similar numbers in each treatment group,
but no description was given for excluded
participants that did not take study medi-
cation
Selective reporting (reporting bias) Low risk No protocol but all expected outcomes re-
ported
Other bias Unclear risk Study sponsors were involved in the design
and conduct of the trial. The data were col-
lected and analysed by the sponsors of the
study
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RE-NOVATE Trial
Methods Study design: Randomised, double-blind, active-controlled trial
Country:Multi-country (16 countries) in Europe, Australia and South Africa
Setting: Multicentre (115 centres); hospital and home; November 2006 to July 2006
Intention-to-treat: No, per-protocol: excluding not treated, no surgery, and inadequate
or no venogram
For the purposes of our meta-analyses we used the reported ITT population of partici-
pants that underwent surgery
Participants Number randomised: Total n = 3493 (220 mg dabigatran n = 1157; 150 mg dabigatran
n = 1174; enoxaparin n = 1162)
Exclusions post randomisation: Total n = 322 (220 mg dabigatran n = 108; 150 mg
dabigatran n = 102; enoxaparin n = 112), reason for all: did not complete study
Losses to follow up: Not specified
Age mean years (SD): 220 mg dabigatran 65 (10); 150 mg dabigatran 63 (11); enoxa-
parin 64 (11)
Sex %F: 220 mg dabigatran 56%; 150 mg dabigatran 57%; enoxaparin 56%
Inclusion criteria: 18 years or older; scheduled to undergo a primary, unilateral, elective
total hip replacement; > 40 kg body weight; gave written informed consent
Exclusion criteria: Patients with an excessive risk of bleeding; active malignant disease
or current cytostatic treatment; known severe renal insufficiency; liver disease expected
to have any potential impact on survival, or elevated AST or ALT > 2 x upper limit of
normal; recent unstable cardiovascular disease or history of myocardial infarction within
the last three months; pre-menopausal women who are pregnant or nursing, or are of
child-bearing potential and are not practising or do not plan to continue practising ac-
ceptable methods of birth control; allergy to radio opaque contrast media or iodine, hep-
arins (including heparin-induced thrombocytopenia) or dabigatran; contraindications
to enoxaparin; participation in a clinical trial during the last 30 days
Interventions Treatment 1*: 150 mg dabigatran etexilate, orally, once daily, starting with half dose
on day of surgery plus one placebo pill identical to other treatment and subcutaneous
placebo injection
Treatment 2*: 220 mg dabigatran etexilate, orally, once daily, starting with half dose on
day of surgery plus one placebo pill identical to other treatment subcutaneous placebo
injection
Control: 40 mg enoxaparin, subcutaneous, once daily plus two placebo pills identical
in appearance to active treatments
Duration: 28 - 35 days (average 33 days)
*For the analyses within this review, the 150 mg and 220 mg treatment groups were
combined as both dosages are considered normal therapeutic dosages
Outcomes Primary: Composite of total VTE and all-cause mortality; VTE includes both proximal
and distal DVT, symptomatic DVT, PE
Secondary:MajorVTEandVTE-related death, proximalDVT, totalDVT, symptomatic
DVT, PE, all-cause mortality, bleeding events
Bleeding definitions: Major bleeding - fatal, clinically overt associated with loss of
haemoglobin greater than or equal to 20g/L or leading to transfusion of greater than or
equal to 2 units of packed cells or whole blood; symptomatic retroperitoneal, intracranial,
intraocular or intraspinal; requiring treatment cessation; leading to reoperation Clini-
cally relevant bleeding - spontaneous skin haematoma greater than or equal to 25 cm
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RE-NOVATE Trial (Continued)
2; wound haematoma greater than or equal to 100 cm2; spontaneous nose bleed lasting
longer than 5 min; macroscopic haematuria spontaneous or lasting longer than 24 hours
if associated with an intervention; spontaneous rectal bleeding (more than a spot on toilet
paper); gingival bleeding lasting longer than 5 min; any other bleeding event considered
clinically relevant by the investigator. Minor bleeding - any other bleeding events that
were not classified as major or clinically relevant
Notes Funding: Steering committee and sponsor responsible for study design, data collection
and analysis done by sponsor, independent data and safety committee monitored study,
steering committee had overall responsibility for all aspects and final responsibility for
decision to submit paper
Method of VTE evaluation/confirmation: DVT detected and confirmed by bilateral
venography; PE confirmed by pulmonary V-Q scintigraphy, chest X-ray, angiography,
spiral CT or autopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by central computer-gen-
erated system, stratified by centre, prepared
in blocks of six
Allocation concealment (selection bias) Low risk Utilised central computer-generated sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All treatment groups received one study
drug and one placebo identical in appear-
ance to the other active treatment as well as
a subcutaneous injection
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Efficacy outcomes initially assessed locally,
then confirmed by blinded, central adjudi-
cation committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All exclusions were reported with reasons
and by study group
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
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RECORD 1 Trial
Methods Study design: Randomised, double-blind trial
Country:Multi-country (27 countries)
Setting: Multi-centre; hospital and home; February 2006 to March 2007
Intention-to-treat: Yes, modified ITT and per-protocol analysis
For the purposes of our meta-analyses we used the reported modified ITT population
of participants that underwent surgery
Participants Number randomised: Total n = 4541 (rivaroxaban n = 2266; enoxaparin n = 2275)
Exclusions post randomisation: Total n = 1177 (rivaroxaban n = 580; enoxaparin n =
597); 57 rivaroxaban and 51 enoxaparin randomised but not included in safety analysis
- did not receive study drug but no further description; excluded from ITT if not treated
and did not undergo surgery and had no suitable venograms (additional 523 rivaroxaban,
546 enoxaparin)
Losses to follow up: No reports of loss-to-follow-up
Age mean years (range): Rivaroxaban 63.1 (18 - 91); enoxaparin 63.3 (18 - 93)
Sex F %: Rivaroxaban 55.2%; enoxaparin 55.8%
Inclusion criteria: Men and women 18 years or older; scheduled to undergo elective
total hip replacement
Exclusion criteria: Scheduled to undergo staged, bilateral hip arthroplasty; pregnant or
breastfeeding; active bleeding or a high risk of bleeding; contraindication for prophylaxis
with enoxaparin; conditions preventing bilateral venography; substantial liver disease;
severe renal impairment; concomitant use of protease inhibitors for the treatment ofHIV;
planned intermittent pneumatic compression; requirement for anticoagulant therapy
that could not be stopped
Interventions Treatment 1: 10 mg rivaroxaban, orally, once daily beginning after surgery
Control: 40 mg enoxaparin, subcutaneously, once daily beginning the evening before
surgery
Duration: 35 days (range 31 - 39); mean duration 33.4 days in rivaroxaban and 33.7 in
enoxaparin group - venography took place
Outcomes Primary: Composite DVT (symptomatic or detected by venography), non-fatal PE or
death from any cause at day 36
Secondary: Major VTE (proximal DVT, non-fatal PE or death from VTE), major
bleeding, DVT, symptomatic VTE, death, lab values and cardiovascular events
Bleeding definitions: Major bleeding - fatal, occurred in a critical organ (e.g., retroperi-
toneal, intracranial, intraocular, and intraspinal bleeding), or required reoperation or
extrasurgical-site bleeding that was clinically overt and was associated with a fall in the
haemoglobin level of at least 2 g per decilitre or that required transfusion of 2 or more
units of whole blood or packed cells
Notes Funding: Bayer Healthcare and Johnson & Johnson: data collected and analysed by
sponsors, steering committee designed and supervised, all authors contributing had access
to all data and analysis and vouch for accuracy and completeness of data reported
Method of VTE evaluation/confirmation: Mandatory bilateral venography the day
after the last dose of the study drug
Risk of bias
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RECORD 1 Trial (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation generated in permuted
blocks and stratification according to cen-
tre by a central telephone system with a
computer-generated randomised list
Allocation concealment (selection bias) Low risk Use of telephone system and computer-
generated randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients received study medication plus
placebo tablets or injection
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by a central, blinded ad-
judication committee
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 57 rivaroxaban and 51 enoxaparin ran-
domised but not included in safety analysis
- did not receive study drug but no reasons
given why
Selective reporting (reporting bias) Low risk No protocol provided but all outcomes re-
ported on
Other bias Unclear risk Data was collected and analysed by the
sponsors: Bayer HealthCare and Johnson
& Johnson
RECORD 2 Trial
Methods Study design: Randomised, double-blind, controlled trial
Country:Multinational (21 countries)
Setting: Multicentre (123 centres); hospital and home; February 2006 to April 2007
Intention-to-treat: Modified ITT: not-treated, did not receive surgery, no readable
venogram
For the purposes of our meta-analyses we used the reported modified ITT population
of participants that underwent surgery
Participants Number randomised: Total n = 2509 (rivaroxaban n = 1252; enoxaparin n = 1257)
Exclusions post randomisation: Total n = 90 (rivaroxaban n = 40; enoxaparin n =
50). Rivaroxaban: 24, enoxaparin: 28 - not taken study medication (no reason why);
rivaroxaban 16 and enoxaparin 22 did not receive surgery
Losses to follow up: Not reported
Age mean years (SD): Rivaroxaban 61.4 (13.2); enoxaparin 61.6 (13.7)
Sex %F: Rivaroxaban 54.3% enoxaparin 53.0%
Inclusion criteria: Aged 18 or older; scheduled to undergo elective total hip replacement
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RECORD 2 Trial (Continued)
Exclusion criteria: Scheduled to undergo staged, bilateral hip arthroplasty; pregnant or
breastfeeding; active bleeding or a high risk of bleeding; contraindication for prophylaxis
with enoxaparin; conditions preventing bilateral venography; substantial liver disease;
severe renal impairment; concomitant use of protease inhibitors for the treatment ofHIV;
use of fibrinolytic therapy; planned intermittent pneumatic compression; requirement
for anticoagulant therapy that could not be stopped
Interventions Treatment: 10 mg rivaroxaban, orally, once daily beginning after surgery plus placebo
injections for 10 - 14 days
Control: 40 mg enoxaparin, subcutaneously, once daily beginning the evening before
surgery and continued for 10 - 14 days and received placebo tablets for the entire study
period
Duration: 31 - 39 days
Outcomes Primary: Composite of any DVT, nonfatal PE and all-cause mortality; incidence of
major bleeding events
Secondary: Major VTE (composite of proximal DVT, non-fatal PE and VTE-related
death); DVT (proximal and distal), symptomatic VTE, on-treatment bleeding, death
Bleeding definitions: Major bleeding - fatal, occurred in a critical organ (e.g., retroperi-
toneal, intracranial, intraocular, and intraspinal bleeding), or required reoperation or
extrasurgical-site bleeding that was clinically overt and was associated with a fall in the
haemoglobin level of at least 2 g per decilitre or that required transfusion of 2 or more
units of whole blood or packed cells
Notes Funding: Bayer HealthCare AG, Johnson & Johnson Pharmaceutical Research and
Development LLC; sponsors involved in design and conduct of trial, data collection
and analysis; all authors had full access to data and analyses and vouch for accuracy and
completeness of data and were involved in decision to submit the manuscript
Method of VTE evaluation/confirmation: DVT confirmed by bilateral venography;
PE confirmed by perfusion/ventilation lung scintigraphy, angiography, chest X-ray or
spiral CT or autopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation generated in permuted
blocks and stratification according to cen-
tre by a central telephone system with a
computer-generated randomised list
Allocation concealment (selection bias) Low risk Use of telephone system and computer-
generated randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients received study medication plus
placebo tablets or injection
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RECORD 2 Trial (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by a central, blinded ad-
judication committee
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants were accounted for, with
similar numbers in each treatment group,
but no description was given for excluded
participants that did not take study medi-
cation
Selective reporting (reporting bias) Low risk No protocol provided but all outcomes re-
ported on
Other bias Unclear risk Funded by Bayer HealthCare and Johnson
& Johnson - study sponsors were involved
in the design and conduct of the trial. The
data were collected and analysed by the
sponsors of the study
SACRE Study
Methods Study design: Randomised trial
Country: France
Setting:Multicentre (65 centres); hospital and home; September 1997 to October 1999
Intention-to-treat: Yes, and per-protocol
For the purposes of our meta-analyses we used the reported ITT population
Participants Number randomised: Total n = 1289 (LMWH n = 644; anticoagulant n = 645)
Exclusions post randomisation: Total n = 10 (LMWH n = 1; anticoagulant n = 9); no
treatment 7 (1 reviparin, 6 acenocoumarol); event at randomisation: 3 acenocoumarol
Losses to follow up: Not reported
Age mean years (SD): LMWH 66 (11); anticoagulant 65 (12)
Sex %F: LMWH 51%; anticoagulant 50%
Inclusion criteria: 18 years or older; scheduled to undergo elective unilateral primary
total hip replacement
Exclusion criteria: Femoral neck fracture; current active bleeding or disorders con-
traindicating anticoagulant therapy; a history of DVT or PE; heparin-induced thrombo-
cytopaenia, peptic ulcer, allergy to radiopaque contrast medium; use of aspirin or ticlo-
pidine hydrochloride; renal insufficiency; liver failure; acute endocarditis; recent stroke;
uncontrolled hypertension; pregnancy; alcoholism; inability to follow instructions
Interventions Treatment: Fixed-dose subcutaneous LMWH reviparin sodium, 4200 anti-Xa IU, be-
ginning 12 hours preoperatively
Treatment 2:After initial LMWHtreatment as described above, crossed over to adjusted-
dose oral anticoagulant acenocoumarol, international normalised ratio, 2 - 3
Duration: 6 weeks after surgery
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SACRE Study (Continued)
Outcomes Primary:Combined clinical events of symptomatic thromboembolic event,major haem-
orrhage or death
Secondary: Minor bleeding
Bleeding definitions: Major bleeding - clinically overt and was associated with a de-
crease in haemoglobin level of more than 20 g/L or required a transfusion of 2 U or more
of packed red blood cells after randomisation or was digestive, intracranial, retroperi-
toneal or intraocular or was located at the surgical site and required reoperation or, ac-
cording to the investigator’s opinion, led to discontinuation of the treatment. Minor
bleeding - clinically overt but not major
Notes Funding: Supported by Knoll France, Investigators received USD 400 per patient in-
cluded in the study and PI received final grant of USD 4000
Method of VTE evaluation/confirmation: Suspected DVT confirmed by venography
or duplex scanning; suspected PE confirmed by ventilation-perfusion or angiography
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...randomized computer-derived treat-
ment schedule” performed at a central lo-
cation, stratified by each centre, balanced
in blocks of four
Allocation concealment (selection bias) Low risk Utilised a centralised computer-derived
randomisation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants or
personnel; most likely unblinded as one
treatment given subcutaneously and the
other orally
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes interpreted by a blinded adjudi-
cation committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Table 1. clearly demonstrates missing par-
ticipants and reasons, although it should be
noted the anticoagulant treatment group
had a higher rate of protocol violations (sta-
tistical tests not performed)
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No indication of other bias
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Zhang 2014
Methods Study design: Randomised trial
Country: China
Setting: Single centre; hospital and outpatient clinic; June 2012 and May 2013
Intention-to-treat: Yes
For the purposes of our analyses we used all participants randomised, as reported by the
study authors
Participants Number randomised: Total n = 40 (extended n = 20; short n = 20)
Exclusions post randomisation: Not stated
Losses to follow up: None
Age mean years (range): Extended 60.1 (37 - 76); short 61.3 (42 - 78)
Sex (F/M): Extended 11/9; Short 12/8
Inclusion criteria:All patients admitted to theCenter for Bone and JointHealth between
June 2012 and May 2013, who were diagnosed with osteonecrosis of the femoral head,
scheduled for elective total hip replacement and provided informed consent
Exclusion criteria: Had Doppler ultrasound performed 48 hrs prior to the surgery
showing DVT; had undergone surgery recently, a history of active major bleeding or a
tendency to bleed; had recent use of anticoagulants, antiplatelets or antifibrinogenics;
were pregnant or nursing baby or did not take measures to prevent pregnancy; had severe
kidney or liver dysfunction or other disease that could interfere with drug metabolism
or blood coagulation
Interventions Treatment: Oral rivaroxaban 10 mg once daily started within 6 - 10 hrs after the surgery
for 35 days
Control: Oral rivaroxaban 10 mg once daily started within 6 - 10 hrs after the surgery
for 7 days followed by no treatment
Duration: 35 days post surgery
Outcomes Primary: Efficacy: haemostatic parameters including thrombin-antithrombin com-
plexes, prothrombin fragment 1 and 2, D-dimer and fibrinogen
Secondary: DVT
Outcomes were recorded pre-operatively (within 48 hours before surgery) and at 1, 7,
and 35 days after surgery
Notes Funding: Not reported
Method of VTE evaluation/confirmation: lower limb ultrasonography
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using random numbers generated by com-
puter prior to the surgery
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants or
personnel
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Zhang 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, similar
numbers in groups, no missing outcome
data
Selective reporting (reporting bias) Low risk All listed outcomes reported on
Other bias Low risk No indication of other bias
DVT: deep vein thrombosis
F: female
IU: international unit
LMWH: low-molecular-weight heparin
M: male
NSAID: non-steroidal anti-inflammatory drug
PE: pulmonary embolism
post-op: post-operatively, after operation
pre-op: prior to operation
VAS: visual analogue scale
V-Q: ventilation-perfusion
VTE: venous thromboembolism
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Comp 2001 Treatment duration only four weeks
EPCAT II Treatment duration only 30 days
Kristensen 1990 Treatment not within scope of review: heparin plus indomethacin versus heparin plus placebo
Manganelli 1998 Treatment duration only 30 days
NPHDO Study Group Treatment duration was extended but not to five weeks
PENTHIFRA PLUS Study Treatment duration only four weeks
Swedish Study Treatment duration for only one month
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D A T A A N D A N A L Y S E S
Comparison 1. Heparin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
5 2329 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.35, 1.01]
1.1 Hip replacement 4 1296 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.36, 1.30]
1.2 Knee replacement 1 723 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.21, 2.92]
1.3 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.05, 1.06]
2 Symptomatic DVT (proximal or
distal)
4 2019 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.39, 1.38]
2.1 Hip replacement 4 1296 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.41, 1.55]
2.2 Knee replacement 1 723 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.12]
3 Symptomatic PE 3 1595 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.16, 2.33]
3.1 Hip replacement 3 872 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.56]
3.2 Knee replacement 1 723 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.24, 8.83]
4 Total VTE (symptomatic and
asymptomatic)
6 2544 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.28, 0.56]
4.1 Hip replacement 5 1511 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.25, 0.56]
4.2 Knee replacement 1 723 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.21, 2.92]
4.3 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.16, 0.90]
5 Asymptomatic DVT 5 1304 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.24, 0.60]
5.1 Hip replacement 4 994 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.21, 0.58]
5.2 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.19, 1.52]
6 All-cause mortality 5 2518 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.31, 3.26]
6.1 Hip replacement 4 1485 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.11, 2.75]
6.2 Knee replacement 1 723 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.65]
6.3 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 4.69 [0.22, 98.42]
7 Adverse events 2 460 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.68, 1.64]
7.1 Hip replacement 2 460 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.68, 1.64]
8 Bleeding - major 5 2500 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.14, 2.46]
8.1 Hip replacement 4 1494 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.10]
8.2 Knee replacement 1 696 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.14, 7.06]
8.3 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Bleeding - minor 5 2500 Odds Ratio (M-H, Fixed, 95% CI) 2.01 [1.43, 2.81]
9.1 Hip replacement 4 1494 Odds Ratio (M-H, Fixed, 95% CI) 2.25 [1.53, 3.30]
9.2 Knee replacement 1 696 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.58, 2.59]
9.3 Hip or knee replacement 1 310 Odds Ratio (M-H, Fixed, 95% CI) 2.79 [0.11, 69.13]
10 Reoperation 1 179 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 Hip replacement 1 179 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Vitamin K antagonists versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.94]
1.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.94]
2 Symptomatic DVT (proximal or
distal)
1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.62]
2.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.62]
3 Symptomatic PE 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.84]
3.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.84]
4 Total VTE (symptomatic and
asymptomatic)
1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]
4.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]
5 All-cause mortality 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Bleeding - major 1 360 Odds Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 71.31]
7.1 Hip replacement 1 360 Odds Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 71.31]
Comparison 3. DOAC versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
1 2419 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.68]
1.1 Hip replacement 1 2419 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.68]
2 Symptomatic DVT (proximal or
distal)
2 2459 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.81]
2.1 Hip replacement 2 2459 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.81]
3 Symptomatic PE 1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.25]
3.1 Hip replacement 1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.25]
4 Total VTE (symptomatic and
asymptomatic)
1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.11, 0.33]
4.1 Hip replacement 1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.11, 0.33]
5 All-cause mortality 1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.66]
5.1 Hip replacement 1 1733 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.66]
6 Adverse events 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.74, 1.03]
6.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.74, 1.03]
7 Bleeding - major 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.02]
7.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.02]
8 Bleeding- clinically relevant
non-major
1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.76, 1.95]
8.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.76, 1.95]
9 Bleeding - minor 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.74, 1.88]
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9.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.74, 1.88]
10 Reoperation 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Wound infection 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.46, 3.86]
11.1 Hip replacement 1 2457 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.46, 3.86]
Comparison 4. Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.09, 2.74]
1.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.09, 2.74]
2 Symptomatic DVT (proximal or
distal)
1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.21]
2.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.21]
3 Symptomatic PE 1 557 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.13]
3.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.13]
4 Total VTE (symptomatic and
asymptomatic)
1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.14, 0.50]
4.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.14, 0.50]
5 Asymptomatic DVT 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.13, 0.54]
5.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.13, 0.54]
6 Asymptomatic distal DVT 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.13, 0.54]
6.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.13, 0.54]
7 All-cause mortality 1 842 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 Knee replacement 1 842 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Bleeding - major 1 557 Odds Ratio (M-H, Fixed, 95% CI) 5.05 [0.24, 105.76]
8.1 Knee replacement 1 557 Odds Ratio (M-H, Fixed, 95% CI) 5.05 [0.24, 105.76]
Comparison 5. Vitamin K antagonists versus heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.85, 3.16]
1.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.85, 3.16]
2 Symptomatic DVT (proximal or
distal)
1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.69, 2.68]
2.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.69, 2.68]
3 Symptomatic PE 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 9.16 [0.49, 170.42]
3.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 9.16 [0.49, 170.42]
4 Total VTE (symptomatic and
asymptomatic)
1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.85, 3.16]
4.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.85, 3.16]
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5 All-cause mortality 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 5.07 [0.24, 105.83]
5.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 5.07 [0.24, 105.83]
6 Bleeding - major 1 1272 Odds Ratio (M-H, Fixed, 95% CI) 3.87 [1.91, 7.85]
6.1 Hip replacement 1 1272 Odds Ratio (M-H, Fixed, 95% CI) 3.87 [1.91, 7.85]
7 Bleeding - minor 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.64, 2.76]
7.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.64, 2.76]
8 Reoperation 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 4.60 [0.99, 21.38]
8.1 Hip replacement 1 1279 Odds Ratio (M-H, Fixed, 95% CI) 4.60 [0.99, 21.38]
Comparison 6. DOAC versus heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE (DVT and
PE)
5 15977 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.28, 1.70]
1.1 Hip replacement 5 15977 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.28, 1.70]
2 Symptomatic DVT (proximal or
distal)
5 15977 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.11, 3.27]
2.1 Hip replacement 5 15977 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.11, 3.27]
3 Symptomatic PE 5 14731 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.43, 1.94]
3.1 Hip replacement 5 14731 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.43, 1.94]
4 Total VTE (symptomatic and
asymptomatic)
4 12447 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.97]
4.1 Hip replacement 4 12447 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.97]
5 Asymptomatic DVT 2 6559 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.19, 1.59]
5.1 Hip replacement 2 6559 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.19, 1.59]
6 Asymptomatic proximal DVT 1 2704 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.46, 1.15]
6.1 Hip replacement 1 2704 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.46, 1.15]
7 Asymptomatic distal DVT 1 2639 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.75, 1.99]
7.1 Hip replacement 1 2639 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.75, 1.99]
8 All-cause mortality 5 14966 Odds Ratio (M-H, Fixed, 95% CI) 1.63 [0.64, 4.16]
8.1 Hip replacement 5 14966 Odds Ratio (M-H, Fixed, 95% CI) 1.63 [0.64, 4.16]
9 Adverse events 3 9908 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.88, 1.05]
9.1 Hip replacement 3 9908 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.88, 1.05]
10 Bleeding - major 5 16199 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.79, 1.54]
10.1 Hip replacement 5 16199 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.79, 1.54]
11 Bleeding - clinically relevant,
non-major
4 15241 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.90, 1.28]
11.1 Hip replacement 4 15241 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.90, 1.28]
12 Bleeding - minor 4 11766 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.82, 1.10]
12.1 Hip replacement 4 11766 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.82, 1.10]
13 Reoperation 4 15241 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.34, 3.24]
13.1 Hip replacement 4 15241 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.34, 3.24]
14 Wound infection 2 6446 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.46, 1.72]
14.1 Hip replacement 2 6446 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.46, 1.72]
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Analysis 1.1. Comparison 1 Heparin versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 8/117 7/110 18.8 % 1.08 [ 0.38, 3.08 ]
Fragmin Trial 4/291 3/133 11.4 % 0.60 [ 0.13, 2.74 ]
French Study 3/85 7/88 18.6 % 0.42 [ 0.11, 1.69 ]
Heit 2000 3/241 5/231 14.1 % 0.57 [ 0.13, 2.41 ]
Subtotal (95% CI) 734 562 63.0 % 0.69 [ 0.36, 1.30 ]
Total events: 18 (Heparin), 22 (Placebo)
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Knee replacement
Heit 2000 4/366 5/357 14.0 % 0.78 [ 0.21, 2.92 ]
Subtotal (95% CI) 366 357 14.0 % 0.78 [ 0.21, 2.92 ]
Total events: 4 (Heparin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Hip or knee replacement
Kolb 2003 2/161 8/149 23.0 % 0.22 [ 0.05, 1.06 ]
Subtotal (95% CI) 161 149 23.0 % 0.22 [ 0.05, 1.06 ]
Total events: 2 (Heparin), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Total (95% CI) 1261 1068 100.0 % 0.59 [ 0.35, 1.01 ]
Total events: 24 (Heparin), 35 (Placebo)
Heterogeneity: Chi2 = 3.16, df = 5 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Chi2 = 1.86, df = 2 (P = 0.39), I2 =0.0%
0.005 0.1 1 10 200
Favours heparin Favours placebo
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Analysis 1.2. Comparison 1 Heparin versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 8/117 4/110 17.0 % 1.94 [ 0.57, 6.65 ]
Fragmin Trial 4/291 3/133 18.0 % 0.60 [ 0.13, 2.74 ]
French Study 3/85 7/88 29.3 % 0.42 [ 0.11, 1.69 ]
Heit 2000 3/241 5/231 22.3 % 0.57 [ 0.13, 2.41 ]
Subtotal (95% CI) 734 562 86.6 % 0.80 [ 0.41, 1.55 ]
Total events: 18 (Heparin), 19 (Placebo)
Heterogeneity: Chi2 = 3.16, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Knee replacement
Heit 2000 1/366 3/357 13.4 % 0.32 [ 0.03, 3.12 ]
Subtotal (95% CI) 366 357 13.4 % 0.32 [ 0.03, 3.12 ]
Total events: 1 (Heparin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 1100 919 100.0 % 0.73 [ 0.39, 1.38 ]
Total events: 19 (Heparin), 22 (Placebo)
Heterogeneity: Chi2 = 3.70, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
0.005 0.1 1 10 200
Favours heparin Favours placebo
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Analysis 1.3. Comparison 1 Heparin versus placebo, Outcome 3 Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 3 Symptomatic PE
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 0/117 3/110 64.1 % 0.13 [ 0.01, 2.56 ]
French Study 0/85 0/88 Not estimable
Heit 2000 0/241 0/231 Not estimable
Subtotal (95% CI) 443 429 64.1 % 0.13 [ 0.01, 2.56 ]
Total events: 0 (Heparin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 Knee replacement
Heit 2000 3/366 2/357 35.9 % 1.47 [ 0.24, 8.83 ]
Subtotal (95% CI) 366 357 35.9 % 1.47 [ 0.24, 8.83 ]
Total events: 3 (Heparin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 809 786 100.0 % 0.61 [ 0.16, 2.33 ]
Total events: 3 (Heparin), 5 (Placebo)
Heterogeneity: Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.86, df = 1 (P = 0.17), I2 =46%
0.005 0.1 1 10 200
Favours heparin Favours placebo
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Analysis 1.4. Comparison 1 Heparin versus placebo, Outcome 4 Total VTE (symptomatic and
asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 11/117 26/110 24.8 % 0.34 [ 0.16, 0.72 ]
DaPP Study 5/113 12/102 12.3 % 0.35 [ 0.12, 1.02 ]
Fragmin Trial 14/291 14/133 18.7 % 0.43 [ 0.20, 0.93 ]
French Study 6/85 17/88 15.8 % 0.32 [ 0.12, 0.85 ]
Heit 2000 3/241 5/231 5.1 % 0.57 [ 0.13, 2.41 ]
Subtotal (95% CI) 847 664 76.8 % 0.37 [ 0.25, 0.56 ]
Total events: 39 (Heparin), 74 (Placebo)
Heterogeneity: Chi2 = 0.66, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
2 Knee replacement
Heit 2000 4/366 5/357 5.1 % 0.78 [ 0.21, 2.92 ]
Subtotal (95% CI) 366 357 5.1 % 0.78 [ 0.21, 2.92 ]
Total events: 4 (Heparin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Hip or knee replacement
Kolb 2003 8/161 18/149 18.1 % 0.38 [ 0.16, 0.90 ]
Subtotal (95% CI) 161 149 18.1 % 0.38 [ 0.16, 0.90 ]
Total events: 8 (Heparin), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Total (95% CI) 1374 1170 100.0 % 0.39 [ 0.28, 0.56 ]
Total events: 51 (Heparin), 97 (Placebo)
Heterogeneity: Chi2 = 1.73, df = 6 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 5.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.09, df = 2 (P = 0.58), I2 =0.0%
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Analysis 1.5. Comparison 1 Heparin versus placebo, Outcome 5 Asymptomatic DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 5 Asymptomatic DVT
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 11/93 23/89 32.4 % 0.38 [ 0.18, 0.85 ]
DaPP Study 3/113 9/102 14.4 % 0.28 [ 0.07, 1.07 ]
Fragmin Trial 10/291 11/133 22.8 % 0.39 [ 0.16, 0.95 ]
French Study 3/85 10/88 14.8 % 0.29 [ 0.08, 1.08 ]
Subtotal (95% CI) 582 412 84.4 % 0.35 [ 0.21, 0.58 ]
Total events: 27 (Heparin), 53 (Placebo)
Heterogeneity: Chi2 = 0.32, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000040)
2 Hip or knee replacement
Kolb 2003 6/161 10/149 15.6 % 0.54 [ 0.19, 1.52 ]
Subtotal (95% CI) 161 149 15.6 % 0.54 [ 0.19, 1.52 ]
Total events: 6 (Heparin), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 743 561 100.0 % 0.38 [ 0.24, 0.60 ]
Total events: 33 (Heparin), 63 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000025)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 1.6. Comparison 1 Heparin versus placebo, Outcome 6 All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 6 All-cause mortality
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Dahl 1997 1/134 1/131 18.0 % 0.98 [ 0.06, 15.79 ]
Fragmin Trial 0/389 1/180 36.6 % 0.15 [ 0.01, 3.79 ]
French Study 0/90 0/89 Not estimable
Heit 2000 1/241 1/231 18.2 % 0.96 [ 0.06, 15.41 ]
Subtotal (95% CI) 854 631 72.8 % 0.56 [ 0.11, 2.75 ]
Total events: 2 (Heparin), 3 (Placebo)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Knee replacement
Heit 2000 1/366 1/357 18.1 % 0.98 [ 0.06, 15.65 ]
Subtotal (95% CI) 366 357 18.1 % 0.98 [ 0.06, 15.65 ]
Total events: 1 (Heparin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
3 Hip or knee replacement
Kolb 2003 2/161 0/149 9.1 % 4.69 [ 0.22, 98.42 ]
Subtotal (95% CI) 161 149 9.1 % 4.69 [ 0.22, 98.42 ]
Total events: 2 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 1381 1137 100.0 % 1.01 [ 0.31, 3.26 ]
Total events: 5 (Heparin), 4 (Placebo)
Heterogeneity: Chi2 = 2.30, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Chi2 = 1.48, df = 2 (P = 0.48), I2 =0.0%
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Analysis 1.7. Comparison 1 Heparin versus placebo, Outcome 7 Adverse events.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 7 Adverse events
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
DaPP Study 58/140 53/141 78.5 % 1.17 [ 0.73, 1.90 ]
French Study 6/90 9/89 21.5 % 0.63 [ 0.22, 1.86 ]
Total (95% CI) 230 230 100.0 % 1.06 [ 0.68, 1.64 ]
Total events: 64 (Heparin), 62 (Placebo)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Heparin versus placebo, Outcome 8 Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 8 Bleeding - major
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
DaPP Study 0/141 1/140 29.8 % 0.33 [ 0.01, 8.14 ]
Fragmin Trial 0/389 0/180 Not estimable
French Study 0/90 0/89 Not estimable
Heit 2000 0/239 1/226 30.5 % 0.31 [ 0.01, 7.74 ]
Subtotal (95% CI) 859 635 60.3 % 0.32 [ 0.03, 3.10 ]
Total events: 0 (Heparin), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 Knee replacement
Heit 2000 2/350 2/346 39.7 % 0.99 [ 0.14, 7.06 ]
Subtotal (95% CI) 350 346 39.7 % 0.99 [ 0.14, 7.06 ]
Total events: 2 (Heparin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
3 Hip or knee replacement
Kolb 2003 0/161 0/149 Not estimable
Subtotal (95% CI) 161 149 Not estimable
Total events: 0 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1370 1130 100.0 % 0.59 [ 0.14, 2.46 ]
Total events: 2 (Heparin), 4 (Placebo)
Heterogeneity: Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 1.9. Comparison 1 Heparin versus placebo, Outcome 9 Bleeding - minor.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 9 Bleeding - minor
Study or subgroup Heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
DaPP Study 18/141 11/140 18.6 % 1.72 [ 0.78, 3.78 ]
Fragmin Trial 80/389 21/180 44.2 % 1.96 [ 1.17, 3.29 ]
French Study 17/90 4/89 6.3 % 4.95 [ 1.59, 15.37 ]
Heit 2000 10/239 3/226 5.7 % 3.25 [ 0.88, 11.95 ]
Subtotal (95% CI) 859 635 74.8 % 2.25 [ 1.53, 3.30 ]
Total events: 125 (Heparin), 39 (Placebo)
Heterogeneity: Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 4.15 (P = 0.000034)
2 Knee replacement
Heit 2000 16/350 13/346 24.2 % 1.23 [ 0.58, 2.59 ]
Subtotal (95% CI) 350 346 24.2 % 1.23 [ 0.58, 2.59 ]
Total events: 16 (Heparin), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
3 Hip or knee replacement
Kolb 2003 1/161 0/149 1.0 % 2.79 [ 0.11, 69.13 ]
Subtotal (95% CI) 161 149 1.0 % 2.79 [ 0.11, 69.13 ]
Total events: 1 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 1370 1130 100.0 % 2.01 [ 1.43, 2.81 ]
Total events: 142 (Heparin), 52 (Placebo)
Heterogeneity: Chi2 = 4.82, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000048)
Test for subgroup differences: Chi2 = 2.04, df = 2 (P = 0.36), I2 =2%
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Analysis 1.10. Comparison 1 Heparin versus placebo, Outcome 10 Reoperation.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 1 Heparin versus placebo
Outcome: 10 Reoperation
Study or subgroup Favours heparin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
French Study 0/90 0/89 Not estimable
Total (95% CI) 90 89 Not estimable
Total events: 0 (Favours heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.1. Comparison 2 Vitamin K antagonists versus placebo, Outcome 1 Symptomatic VTE (DVT and
PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup Favours VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 0/184 4/176 100.0 % 0.10 [ 0.01, 1.94 ]
Total (95% CI) 184 176 100.0 % 0.10 [ 0.01, 1.94 ]
Total events: 0 (Favours VKA), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Vitamin K antagonists versus placebo, Outcome 2 Symptomatic DVT (proximal
or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup Favours VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 0/184 3/176 100.0 % 0.13 [ 0.01, 2.62 ]
Total (95% CI) 184 176 100.0 % 0.13 [ 0.01, 2.62 ]
Total events: 0 (Favours VKA), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Vitamin K antagonists versus placebo, Outcome 3 Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 3 Symptomatic PE
Study or subgroup Favours VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 0/184 1/176 100.0 % 0.32 [ 0.01, 7.84 ]
Total (95% CI) 184 176 100.0 % 0.32 [ 0.01, 7.84 ]
Total events: 0 (Favours VKA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Vitamin K antagonists versus placebo, Outcome 4 Total VTE (symptomatic and
asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup Favours VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 1/184 9/176 100.0 % 0.10 [ 0.01, 0.81 ]
Total (95% CI) 184 176 100.0 % 0.10 [ 0.01, 0.81 ]
Total events: 1 (Favours VKA), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Vitamin K antagonists versus placebo, Outcome 5 All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 5 All-cause mortality
Study or subgroup VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 0/184 0/176 Not estimable
Total (95% CI) 184 176 Not estimable
Total events: 0 (VKA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.6. Comparison 2 Vitamin K antagonists versus placebo, Outcome 6 Adverse events.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 6 Adverse events
Study or subgroup VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 0/184 0/176 Not estimable
Total (95% CI) 184 176 Not estimable
Total events: 0 (VKA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.7. Comparison 2 Vitamin K antagonists versus placebo, Outcome 7 Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 2 Vitamin K antagonists versus placebo
Outcome: 7 Bleeding - major
Study or subgroup VKA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
Prandoni 2002 1/184 0/176 100.0 % 2.89 [ 0.12, 71.31 ]
Total (95% CI) 184 176 100.0 % 2.89 [ 0.12, 71.31 ]
Total events: 1 (VKA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 DOAC versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 3/1212 15/1207 100.0 % 0.20 [ 0.06, 0.68 ]
Total (95% CI) 1212 1207 100.0 % 0.20 [ 0.06, 0.68 ]
Total events: 3 (DOAC), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 DOAC versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 2/1212 11/1207 100.0 % 0.18 [ 0.04, 0.81 ]
Zhang 2014 0/20 0/20 Not estimable
Total (95% CI) 1232 1227 100.0 % 0.18 [ 0.04, 0.81 ]
Total events: 2 (DOAC), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 DOAC versus placebo, Outcome 3 Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 3 Symptomatic PE
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 1/864 4/869 100.0 % 0.25 [ 0.03, 2.25 ]
Total (95% CI) 864 869 100.0 % 0.25 [ 0.03, 2.25 ]
Total events: 1 (DOAC), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 DOAC versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 15/864 75/869 100.0 % 0.19 [ 0.11, 0.33 ]
Total (95% CI) 864 869 100.0 % 0.19 [ 0.11, 0.33 ]
Total events: 15 (DOAC), 75 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 DOAC versus placebo, Outcome 5 All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 5 All-cause mortality
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 2/864 6/869 100.0 % 0.33 [ 0.07, 1.66 ]
Total (95% CI) 864 869 100.0 % 0.33 [ 0.07, 1.66 ]
Total events: 2 (DOAC), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 DOAC versus placebo, Outcome 6 Adverse events.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 6 Adverse events
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 768/1228 807/1229 100.0 % 0.87 [ 0.74, 1.03 ]
Total (95% CI) 1228 1229 100.0 % 0.87 [ 0.74, 1.03 ]
Total events: 768 (DOAC), 807 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 DOAC versus placebo, Outcome 7 Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 7 Bleeding - major
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 1/1228 1/1229 100.0 % 1.00 [ 0.06, 16.02 ]
Total (95% CI) 1228 1229 100.0 % 1.00 [ 0.06, 16.02 ]
Total events: 1 (DOAC), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 DOAC versus placebo, Outcome 8 Bleeding- clinically relevant non-major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 8 Bleeding- clinically relevant non-major
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 40/1228 33/1229 100.0 % 1.22 [ 0.76, 1.95 ]
Total (95% CI) 1228 1229 100.0 % 1.22 [ 0.76, 1.95 ]
Total events: 40 (DOAC), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 DOAC versus placebo, Outcome 9 Bleeding - minor.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 9 Bleeding - minor
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 40/1228 34/1229 100.0 % 1.18 [ 0.74, 1.88 ]
Total (95% CI) 1228 1229 100.0 % 1.18 [ 0.74, 1.88 ]
Total events: 40 (DOAC), 34 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours DOAC Favours placebo
88Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.10. Comparison 3 DOAC versus placebo, Outcome 10 Reoperation.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 10 Reoperation
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 0/1228 0/1229 Not estimable
Total (95% CI) 1228 1229 Not estimable
Total events: 0 (DOAC), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.11. Comparison 3 DOAC versus placebo, Outcome 11 Wound infection.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 3 DOAC versus placebo
Outcome: 11 Wound infection
Study or subgroup DOAC Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RECORD 2 Trial 8/1228 6/1229 100.0 % 1.34 [ 0.46, 3.86 ]
Total (95% CI) 1228 1229 100.0 % 1.34 [ 0.46, 3.86 ]
Total events: 8 (DOAC), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 1
Symptomatic VTE (DVT and PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 2/278 4/279 100.0 % 0.50 [ 0.09, 2.74 ]
Total (95% CI) 278 279 100.0 % 0.50 [ 0.09, 2.74 ]
Total events: 2 (Anticoagulant), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 2
Symptomatic DVT (proximal or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 1/278 3/279 100.0 % 0.33 [ 0.03, 3.21 ]
Total (95% CI) 278 279 100.0 % 0.33 [ 0.03, 3.21 ]
Total events: 1 (Anticoagulant), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 3
Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 3 Symptomatic PE
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 1/278 1/279 100.0 % 1.00 [ 0.06, 16.13 ]
Total (95% CI) 278 279 100.0 % 1.00 [ 0.06, 16.13 ]
Total events: 1 (Anticoagulant), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 4
Total VTE (symptomatic and asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 13/278 44/279 100.0 % 0.26 [ 0.14, 0.50 ]
Total (95% CI) 278 279 100.0 % 0.26 [ 0.14, 0.50 ]
Total events: 13 (Anticoagulant), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.08 (P = 0.000045)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 5
Asymptomatic DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 5 Asymptomatic DVT
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 10/278 35/279 100.0 % 0.26 [ 0.13, 0.54 ]
Total (95% CI) 278 279 100.0 % 0.26 [ 0.13, 0.54 ]
Total events: 10 (Anticoagulant), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00027)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 6
Asymptomatic distal DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 6 Asymptomatic distal DVT
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 10/278 35/279 100.0 % 0.26 [ 0.13, 0.54 ]
Total (95% CI) 278 279 100.0 % 0.26 [ 0.13, 0.54 ]
Total events: 10 (Anticoagulant), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00027)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 7
All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 7 All-cause mortality
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 0/422 0/420 Not estimable
Total (95% CI) 422 420 Not estimable
Total events: 0 (Anticoagulant), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 4.8. Comparison 4 Anticoagulant (chosen at investigators’ discretion) versus placebo, Outcome 8
Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 4 Anticoagulant (chosen at investigators’ discretion) versus placebo
Outcome: 8 Bleeding - major
Study or subgroup Anticoagulant Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Knee replacement
Barrellier 2010 2/278 0/279 100.0 % 5.05 [ 0.24, 105.76 ]
Total (95% CI) 278 279 100.0 % 5.05 [ 0.24, 105.76 ]
Total events: 2 (Anticoagulant), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Vitamin K antagonists versus heparin, Outcome 1 Symptomatic VTE (DVT and
PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 24/636 15/643 100.0 % 1.64 [ 0.85, 3.16 ]
Total (95% CI) 636 643 100.0 % 1.64 [ 0.85, 3.16 ]
Total events: 24 (VKA), 15 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Vitamin K antagonists versus heparin, Outcome 2 Symptomatic DVT (proximal
or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 20/636 15/643 100.0 % 1.36 [ 0.69, 2.68 ]
Total (95% CI) 636 643 100.0 % 1.36 [ 0.69, 2.68 ]
Total events: 20 (VKA), 15 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Vitamin K antagonists versus heparin, Outcome 3 Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 3 Symptomatic PE
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 4/636 0/643 100.0 % 9.16 [ 0.49, 170.42 ]
Total (95% CI) 636 643 100.0 % 9.16 [ 0.49, 170.42 ]
Total events: 4 (VKA), 0 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Vitamin K antagonists versus heparin, Outcome 4 Total VTE (symptomatic and
asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 24/636 15/643 100.0 % 1.64 [ 0.85, 3.16 ]
Total (95% CI) 636 643 100.0 % 1.64 [ 0.85, 3.16 ]
Total events: 24 (VKA), 15 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Vitamin K antagonists versus heparin, Outcome 5 All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 5 All-cause mortality
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 2/636 0/643 100.0 % 5.07 [ 0.24, 105.83 ]
Total (95% CI) 636 643 100.0 % 5.07 [ 0.24, 105.83 ]
Total events: 2 (VKA), 0 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Vitamin K antagonists versus heparin, Outcome 6 Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 6 Bleeding - major
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 37/636 10/636 100.0 % 3.87 [ 1.91, 7.85 ]
Total (95% CI) 636 636 100.0 % 3.87 [ 1.91, 7.85 ]
Total events: 37 (VKA), 10 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 3.75 (P = 0.00018)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Vitamin K antagonists versus heparin, Outcome 7 Bleeding - minor.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 7 Bleeding - minor
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 17/636 13/643 100.0 % 1.33 [ 0.64, 2.76 ]
Total (95% CI) 636 643 100.0 % 1.33 [ 0.64, 2.76 ]
Total events: 17 (VKA), 13 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 5.8. Comparison 5 Vitamin K antagonists versus heparin, Outcome 8 Reoperation.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 5 Vitamin K antagonists versus heparin
Outcome: 8 Reoperation
Study or subgroup VKA heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
SACRE Study 9/636 2/643 100.0 % 4.60 [ 0.99, 21.38 ]
Total (95% CI) 636 643 100.0 % 4.60 [ 0.99, 21.38 ]
Total events: 9 (VKA), 2 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 DOAC versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 1 Symptomatic VTE (DVT and PE)
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Hip replacement
ADVANCE 3 4/2708 10/2699 23.4 % 0.40 [ 0.12, 1.27 ]
EXTEND Study 2/386 2/357 13.5 % 0.92 [ 0.13, 6.60 ]
RE-NOVATE II Trial 1/1001 6/992 12.2 % 0.16 [ 0.02, 1.37 ]
RE-NOVATE Trial 21/2293 4/1142 24.8 % 2.63 [ 0.90, 7.68 ]
RECORD 1 Trial 6/2193 11/2206 26.1 % 0.55 [ 0.20, 1.48 ]
Total (95% CI) 8581 7396 100.0 % 0.70 [ 0.28, 1.70 ]
Total events: 34 (DOAC), 33 (heparin)
Heterogeneity: Tau2 = 0.54; Chi2 = 8.82, df = 4 (P = 0.07); I2 =55%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 DOAC versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 2 Symptomatic DVT (proximal or distal)
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Hip replacement
ADVANCE 3 1/2708 5/2699 21.2 % 0.20 [ 0.02, 1.70 ]
EXTEND Study 1/386 0/357 15.0 % 2.78 [ 0.11, 68.51 ]
RE-NOVATE II Trial 0/1001 4/992 16.4 % 0.11 [ 0.01, 2.04 ]
RE-NOVATE Trial 15/2293 1/1142 22.0 % 7.51 [ 0.99, 56.95 ]
RECORD 1 Trial 2/2193 10/2206 25.5 % 0.20 [ 0.04, 0.92 ]
Total (95% CI) 8581 7396 100.0 % 0.60 [ 0.11, 3.27 ]
Total events: 19 (DOAC), 20 (heparin)
Heterogeneity: Tau2 = 2.36; Chi2 = 11.44, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 DOAC versus heparin, Outcome 3 Symptomatic PE.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 3 Symptomatic PE
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 3/2708 5/2699 35.5 % 0.60 [ 0.14, 2.50 ]
EXTEND Study 1/386 2/357 14.7 % 0.46 [ 0.04, 5.11 ]
RE-NOVATE II Trial 1/1001 2/992 14.2 % 0.50 [ 0.04, 5.47 ]
RE-NOVATE Trial 6/2293 3/1142 28.4 % 1.00 [ 0.25, 3.99 ]
RECORD 1 Trial 4/1595 1/1558 7.2 % 3.91 [ 0.44, 35.06 ]
Total (95% CI) 7983 6748 100.0 % 0.91 [ 0.43, 1.94 ]
Total events: 15 (DOAC), 13 (heparin)
Heterogeneity: Chi2 = 2.61, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 DOAC versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 4 Total VTE (symptomatic and asymptomatic)
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Hip replacement
ADVANCE 3 24/1949 73/1917 24.8 % 0.31 [ 0.20, 0.50 ]
RE-NOVATE II Trial 61/1001 69/992 26.4 % 0.87 [ 0.61, 1.24 ]
RE-NOVATE Trial 67/2293 36/1142 25.6 % 0.92 [ 0.61, 1.40 ]
RECORD 1 Trial 16/1595 54/1558 23.2 % 0.28 [ 0.16, 0.50 ]
Total (95% CI) 6838 5609 100.0 % 0.53 [ 0.29, 0.97 ]
Total events: 168 (DOAC), 232 (heparin)
Heterogeneity: Tau2 = 0.33; Chi2 = 22.80, df = 3 (P = 0.00004); I2 =87%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 DOAC versus heparin, Outcome 5 Asymptomatic DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 5 Asymptomatic DVT
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Hip replacement
ADVANCE 3 21/1944 63/1911 48.5 % 0.32 [ 0.19, 0.53 ]
RE-NOVATE Trial 103/1790 56/914 51.5 % 0.94 [ 0.67, 1.31 ]
Total (95% CI) 3734 2825 100.0 % 0.56 [ 0.19, 1.59 ]
Total events: 124 (DOAC), 119 (heparin)
Heterogeneity: Tau2 = 0.53; Chi2 = 12.31, df = 1 (P = 0.00045); I2 =92%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 DOAC versus heparin, Outcome 6 Asymptomatic proximal DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 6 Asymptomatic proximal DVT
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RE-NOVATE Trial 46/1790 32/914 100.0 % 0.73 [ 0.46, 1.15 ]
Total (95% CI) 1790 914 100.0 % 0.73 [ 0.46, 1.15 ]
Total events: 46 (DOAC), 32 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 DOAC versus heparin, Outcome 7 Asymptomatic distal DVT.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 7 Asymptomatic distal DVT
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RE-NOVATE Trial 57/1745 24/894 100.0 % 1.22 [ 0.75, 1.99 ]
Total (95% CI) 1745 894 100.0 % 1.22 [ 0.75, 1.99 ]
Total events: 57 (DOAC), 24 (heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 DOAC versus heparin, Outcome 8 All-cause mortality.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 8 All-cause mortality
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 3/2708 1/2699 13.9 % 2.99 [ 0.31, 28.78 ]
EXTEND Study 0/479 0/479 Not estimable
RE-NOVATE II Trial 0/1010 1/1003 20.9 % 0.33 [ 0.01, 8.13 ]
RE-NOVATE Trial 6/2293 0/1142 9.2 % 6.49 [ 0.37, 115.36 ]
RECORD 1 Trial 4/1595 4/1558 56.0 % 0.98 [ 0.24, 3.91 ]
Total (95% CI) 8085 6881 100.0 % 1.63 [ 0.64, 4.16 ]
Total events: 13 (DOAC), 6 (heparin)
Heterogeneity: Chi2 = 2.64, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 DOAC versus heparin, Outcome 9 Adverse events.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 9 Adverse events
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RE-NOVATE II Trial 684/1010 696/1003 22.2 % 0.93 [ 0.77, 1.12 ]
RE-NOVATE Trial 1774/2308 892/1154 27.0 % 0.98 [ 0.82, 1.15 ]
RECORD 1 Trial 1413/2209 1439/2224 50.8 % 0.97 [ 0.86, 1.10 ]
Total (95% CI) 5527 4381 100.0 % 0.96 [ 0.88, 1.05 ]
Total events: 3871 (DOAC), 3027 (heparin)
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 DOAC versus heparin, Outcome 10 Bleeding - major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 10 Bleeding - major
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 22/2673 18/2659 26.7 % 1.22 [ 0.65, 2.28 ]
EXTEND Study 8/479 15/479 22.0 % 0.53 [ 0.22, 1.25 ]
RE-NOVATE II Trial 14/1010 9/1003 13.3 % 1.55 [ 0.67, 3.60 ]
RE-NOVATE Trial 38/2309 18/1154 35.2 % 1.06 [ 0.60, 1.86 ]
RECORD 1 Trial 6/2209 2/2224 3.0 % 3.03 [ 0.61, 15.01 ]
Total (95% CI) 8680 7519 100.0 % 1.11 [ 0.79, 1.54 ]
Total events: 88 (DOAC), 62 (heparin)
Heterogeneity: Chi2 = 5.08, df = 4 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 6.11. Comparison 6 DOAC versus heparin, Outcome 11 Bleeding - clinically relevant, non-major.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 11 Bleeding - clinically relevant, non-major
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 109/2673 120/2659 48.4 % 0.90 [ 0.69, 1.17 ]
RE-NOVATE II Trial 23/1010 20/1003 8.2 % 1.15 [ 0.62, 2.10 ]
RE-NOVATE Trial 103/2309 40/1154 21.4 % 1.30 [ 0.90, 1.89 ]
RECORD 1 Trial 65/2209 54/2224 21.9 % 1.22 [ 0.85, 1.76 ]
Total (95% CI) 8201 7040 100.0 % 1.08 [ 0.90, 1.28 ]
Total events: 300 (DOAC), 234 (heparin)
Heterogeneity: Chi2 = 3.23, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 DOAC versus heparin, Outcome 12 Bleeding - minor.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 12 Bleeding - minor
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 184/2673 200/2659 53.3 % 0.91 [ 0.74, 1.12 ]
EXTEND Study 18/479 21/479 5.8 % 0.85 [ 0.45, 1.62 ]
RE-NOVATE II Trial 61/1010 54/1003 14.5 % 1.13 [ 0.77, 1.65 ]
RE-NOVATE Trial 142/2309 74/1154 26.4 % 0.96 [ 0.72, 1.28 ]
Total (95% CI) 6471 5295 100.0 % 0.95 [ 0.82, 1.10 ]
Total events: 405 (DOAC), 349 (heparin)
Heterogeneity: Chi2 = 1.10, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 6.13. Comparison 6 DOAC versus heparin, Outcome 13 Reoperation.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 13 Reoperation
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
ADVANCE 3 1/2673 1/2659 16.7 % 0.99 [ 0.06, 15.91 ]
RE-NOVATE II Trial 0/1010 0/1003 Not estimable
RE-NOVATE Trial 5/2309 3/1154 66.6 % 0.83 [ 0.20, 3.49 ]
RECORD 1 Trial 2/2209 1/2224 16.6 % 2.01 [ 0.18, 22.23 ]
Total (95% CI) 8201 7040 100.0 % 1.06 [ 0.34, 3.24 ]
Total events: 8 (DOAC), 5 (heparin)
Heterogeneity: Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 6.14. Comparison 6 DOAC versus heparin, Outcome 14 Wound infection.
Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Comparison: 6 DOAC versus heparin
Outcome: 14 Wound infection
Study or subgroup DOAC heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hip replacement
RE-NOVATE II Trial 9/1010 11/1003 57.9 % 0.81 [ 0.33, 1.97 ]
RECORD 1 Trial 8/2209 8/2224 42.1 % 1.01 [ 0.38, 2.69 ]
Total (95% CI) 3219 3227 100.0 % 0.89 [ 0.46, 1.72 ]
Total events: 17 (DOAC), 19 (heparin)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Thrombosis] this term only 1309
#2 MeSH descriptor: [Thromboembolism] this term only 1067
#3 MeSHdescriptor: [VenousThromboembolism] this term only 461
#4 MeSH descriptor: [Venous Thrombosis] this term only 1060
#5 (thromboprophyla* or thrombus* or thrombotic* or throm-
bolic* or thromboemboli* or thrombos* or embol*):ti,ab,kw
17234
#6 MeSH descriptor: [Pulmonary Embolism] explode all trees 944
#7 PE or DVT or VTE:ti,ab,kw 4161
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(Continued)
#8 (vein* or ven*) near thromb*:ti,ab,kw 6917
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 20147
#10 MeSH descriptor: [Anticoagulants] explode all trees 4058
#11 anticoagul* or anti-coagu* or antithrombotic* 9328
#12 warfarin or (vitamin near/3 antagonist*) or VKA or
Nicoumalone or phenindione or acenocoumarol* or
Sinthrome or dicoumarol* or nicoumalone or phenpro-
coumon or Marcoumar or Marcumar or Falithrom or AVK
or bishydroxycoumarin* or coumarin* or coumadin* or phen-
procoumon*
4024
#13 Ximelagatran or Exanta or Exarta or H 376/95 or dabigatran
or rivaroxaban or Xarelto
874
#14 fondaparinux or Arixtra or BAY59-7939 or TTP889 or odi-
parcil or LY517717 or YM150 or DU-176b
395
#15 apixaban or betrixaban or edoxaban or idraparinux 402
#16 LMWH or UFH or heparin or nadroparin* or fraxiparin* or
enoxaparin
9899
#17 Clexane or klexane or lovenox or dalteparin or Fragmin or
ardeparin
762
#18 normiflo or tinzaparin or logiparin or Innohep or certoparin
or sandoparin or reviparin or clivarin*
432
#19 danaproid or danaparoid or antixarin or ardeparin* or bemi-
parin*
136
#20 Zibor or cy 222 or embolex or monoembolex or parnaparin* 128
#21 rd 11885 or tedelparin or Kabi-2165 or Kabi 2165 78
#22 emt-966 or emt-967 or “pk-10 169” or pk-10169 or pk10169
or cy-216 or cy216
83
#23 seleparin* or tedegliparin or seleparin* or tedegliparin* 19
#24 wy90493 or “wy 90493” or “kb 101” or kb101 21
113Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#25 lomoparan or orgaran or parnaparin or fluxum or lohepa or
lowhepa or “op 2123” or parvoparin or AVE5026
113
#26 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #
18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
17458
#27 MeSH descriptor: [Hip] explode all trees 309
#28 MeSH descriptor: [Knee] explode all trees 584
#29 hip:ti,ab,kw (Word variations have been searched) 11495
#30 knee:ti,ab,kw (Word variations have been searched) 13133
#31 orthop?edic 6896
#32 MeSH descriptor: [Orthopedic Procedures] explode all trees 10000
#33 #27 or #28 or #29 or #30 or #31 or #32 31372
#34 #9 and #26 and #33 1182
Appendix 2. Additional Summary of findings table: Heparin compared to placebo for prevention of
venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: heparin
Comparison: placebo
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with hep-
arin
To-
tal VTE (symp-
tomatic and
asymptomatic)
Study population OR 0.39
(0.28 to 0.56)
2544
(6 RCTs)
⊕⊕⊕⊕
HIGH
-
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(Continued)
Treatment dura-
tion 28 - 42 days
83 per 1000 34 per 1000
(25 to 48)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
Study population OR 0.38
(0.24 to 0.60)
1304
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
112 per 1000 46 per 1000
(29 to 71)
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
see comment not estimable - - asymptomatic
and prox-
imal DVT re-
ported separately
but due to avail-
able data it was
not possible to
determine which
events fell into
which category
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
see comment not estimable - - asymptomatic
and distal DVT
reported sep-
arately but due
to available data
it was not possi-
ble to determine
which events fell
into which cate-
gory
All-cause
mortality
Treatment dura-
tion 28 - 42 days
Study population OR 1.01
(0.31 to 3.26)
2518
(5 RCTs)
⊕⊕⊕©
MODERATE 1
-
4 per 1000 4 per 1000
(1 to 11)
Adverse events
Treatment dura-
tion 28 - 42 days
Study population OR 1.06
(0.68 to 1.64)
460
(2 RCTs)
⊕⊕⊕©
MODERATE 2
-
270 per 1000 281 per 1000
(201 to 377)
Reoperation
Treatment dura-
see comment - 179
(1 RCT)
- one study
reported no op-
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(Continued)
tion 28 - 42 days erations in either
study arm. Three
studies did not
report on reop-
eration and two
studies did not
report sufficient
data to analyse
Wound
infection
Treatment dura-
tion 28 - 42 days
see comment - - - four stud-
ies did not report
on wound infec-
tion. Two stud-
ies did not pro-
vide specific de-
tails for wound
infection
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level, low number of events leading to imprecision of results
2 Downgraded by one level due to imprecision
Appendix 3. Additional Summary of findings table: Vitamin K antagonists compared to placebo for
prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair
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Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replace-
ment or hip fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: vitamin K antagonists
Comparison: placebo
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with vita-
min K antago-
nists
To-
tal VTE (symp-
tomatic and
asymptomatic)
Treatment dura-
tion 28 - 42 days
Study population OR 0.10
(0.01 to 0.81)
360
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
51 per 1000 5 per 1000
(1 to 42)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
All-cause
mortality
Treatment dura-
tion 28 - 42 days
see comment - 360
(1 RCT)
- single in-
cluded study re-
ported no deaths
in either study
arm so not possi-
ble to assess risk
Adverse events
Treatment dura-
tion 28 - 42 days
see comment - 360
(1 RCT)
- single in-
cluded study re-
ported no ad-
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(Continued)
verse events in ei-
ther study arm
so not possible to
assess risk
Reoperation
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Wound
infection
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level, results from a single study only so heterogeneity could not be assessed
Appendix 4. Additional Summary of findings table: DOAC compared to placebo for prevention of
venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: DOAC
Comparison: placebo
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(Continued)
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with
DOAC
To-
tal VTE (symp-
tomatic and
asymptomatic)
Treatment dura-
tion 28 - 42 days
Study population OR 0.19
(0.11 to 0.33)
1733
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
86 per 1000 18 per 1000
(10 to 30)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
All-cause
mortality
Treatment dura-
tion 28 - 42 days
Study population OR 0.33
(0.07 to 1.66)
1733
(1 RCT)
⊕⊕©©
LOW 12
-
7 per 1000 2 per 1000
(0 to 11)
Adverse events
Treatment dura-
tion 28 - 42 days
Study population OR 0.87
(0.74 to 1.03)
2457
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
657 per 1000 625 per 1000
(586 to 663)
Reoperation
Treatment dura-
tion 28 - 42 days
see comment - 2457
(1 RCT)
- single study re-
ported no cases
of reoperation in
the study arms
Wound
infection
Treatment dura-
Study population OR 1.34
(0.46 to 3.86)
2457
(1 RCT)
⊕⊕©©
LOW 12
-
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(Continued)
tion 28 - 42 days
5 per 1000 7 per 1000
(2 to 19)
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DOAC: direct oral anticoagulant; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism;
RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level, results from a single study so heterogeneity cannot be assessed
2 Downgraded by one level, low number of events leading to wide CI and imprecision of results
Appendix 5. Additional Summary of findings table: Anticoagulants (chosen at investigators’
discretion) compared to placebo for prevention of venous thromboembolism following total hip or
knee replacement or hip fracture repair
Anticoagulants (chosen at investigators’ discretion) compared to placebo for prevention of venous thromboembolism following
total hip or knee replacement or hip fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: anticoagulant (chosen at investigators’ discretion)
Comparison: placebo
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
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(Continued)
Risk with
placebo
Risk with anti-
coagulant (cho-
sen at investiga-
tors’ discretion)
To-
tal VTE (symp-
tomatic and
asymptomatic)
Treatment dura-
tion 28 - 42 days
Study population OR 0.26
(0.14 to 0.50)
557
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
158 per 1000 46 per 1000
(26 to 86)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
Study population OR 0.26
(0.13 to 0.54)
557
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
125 per 1000 36 per 1000
(18 to 72)
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
Study population OR 0.26
(0.13 to 0.54)
557
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
125 per 1000 36 per 1000
(18 to 72)
All-cause
mortality
Treatment dura-
tion 28 - 42 days
see comment - 842
(1 RCT)
- the single in-
cluded study re-
ported no deaths
in either study
arm
Adverse events
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Reoperation
Treatment dura-
tion 28 - 42 days
see comment - - - outcome
reported as part
of the definition
of the outcome
major bleeding
but data not re-
ported separately
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(Continued)
Wound
infection
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: Ccnfidence interval; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level, results from a single study so heterogeneity could not be assessed
Appendix 6. Additional Summary of findings table: Vitamin K antagonists compared to heparin for
prevention of venous thromboembolism following total hip or knee replacement or hip fracture
repair
Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replace-
ment or hip fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: vitamin K antagonists
Comparison: heparin
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with hep-
arin
Risk with vita-
min K antago-
nists
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(Continued)
To-
tal VTE (symp-
tomatic and
asymptomatic)
Treatment dura-
tion 28 - 42 days
Study population OR 1.64
(0.85 to 3.16)
1279
(1 RCT)
⊕⊕©©
LOW 12
-
23 per 1000 38 per 1000
(20 to 70)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
All-cause
mortality
Treatment dura-
tion 28 - 42 days
see comment OR 5.07
(0.24 to 105.83)
1279
(1 RCT)
⊕⊕©©
LOW 13
no cases of death
reported in the
heparin study
arm
Adverse events
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Reoperation
Treatment dura-
tion 28 - 42 days
Study population OR 4.60
(0.99 to 21.38)
1279
(1 RCT)
⊕⊕©©
LOW 13
-
3 per 1000 14 per 1000
(3 to 63)
Wound
infection
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not reported in
single in-
cluded study in
this comparison
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(Continued)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism; RCT: randomised controlled trial;
VKA: vitamin K antagonist; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level, single study so heterogeneity could not be assessed
2 Downgraded by one level, wide CI
3 Downgraded by one level, low number of events leading to imprecision of results
Appendix 7. Additional Summary of findings table: DOAC compared to heparin for people
requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee re-
placement or hip fracture repair
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip
fracture repair
Setting: hospital and outpatient setting
Intervention: DOAC
Comparison: heparin
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with hep-
arin
Risk with
DOAC
To-
tal VTE (symp-
tomatic and
asymptomatic)
Treatment dura-
tion 28 - 42 days
Study population OR 0.53
(0.29 to 0.97)
12447
(4 RCTs)
⊕⊕⊕©
MODERATE 1
-
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(Continued)
41 per 1000 22 per 1000
(12 to 40)
Asymptomatic
DVT
Treatment dura-
tion 28 - 42 days
Study population OR 0.56
(0.19 to 1.59)
6559
(2 RCTs)
⊕⊕©©
LOW 2
-
42 per 1000 24 per 1000
(8 to 65)
Asymptomatic
proximal DVT
Treatment dura-
tion 28 - 42 days
Study population OR 0.73
(0.46 to 1.15)
2704
(1 RCT)
⊕⊕⊕©
MODERATE 3
-
35 per 1000 26 per 1000
(16 to 40)
Asymptomatic
distal DVT
Treatment dura-
tion 28 - 42 days
Study population OR 1.22
(0.75 to 1.99)
2639
(1 RCT)
⊕⊕⊕©
MODERATE 3
-
27 per 1000 33 per 1000
(20 to 52)
All-cause
mortality
Treatment dura-
tion 28 - 42 days
Study population OR 1.63
(0.64 to 4.16)
14966
(5 RCTs)
⊕⊕⊕©
MODERATE 4
-
1 per 1000 1 per 1000
(1 to 4)
Adverse events
Treatment dura-
tion 28 - 42 days
Study population OR 0.96
(0.88 to 1.05)
9908
(3 RCTs)
⊕⊕⊕⊕
HIGH
-
691 per 1000 682 per 1000
(663 to 701)
Reoperation
Treatment dura-
tion 28 - 42 days
Study population OR 1.06
(0.34 to 3.24)
15241
(4 RCTs)
⊕⊕⊕©
MODERATE 4
-
1 per 1000 1 per 1000
(0 to 2)
Wound
infection
Treatment dura-
tion 28 - 42 days
Study population OR 0.89
(0.46 to 1.72)
6446
(2 RCTs)
⊕⊕⊕©
MODERATE 4
-
6 per 1000 5 per 1000
(3 to 10)
Wound healing
Treatment dura-
tion 28 - 42 days
see comment - - - not re-
ported in five in-
cluded studies in
this comparison
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(Continued)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DOAC: direct oral anticoagulant; DVT: deep vein thrombosis; OR: odds ratio; PE: pulmonary embolism;
RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality:We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded by one level for inconsistency (heterogeneity, I2 = 87%)
2 Downgraded by two levels for serious inconsistency (heterogeneity, I2 = 92%)
3 Downgraded by one level, single included study so unable to assess heterogeneity
4 Downgraded by one level, few events leading to wide CI and imprecision
F E E D B A C K
Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this protocol, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit
website at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 3, 2016
Date Event Description
14 February 2011 Amended Link to anticoagulant feedback added
1 October 2008 Amended Converted to new review format.
11 January 2002 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
New authors have taken over this review.
The outcome ’Total VTE’ was added as several studies did not report VTE (specifically DVT) as symptomatic or asymptomatic, making
it difficult to place within the previously listed outcome definitions. This way more data could be combined for comparison, but needed
to be done with caution as the outcomes would be more heterogenous.
’Clinically relevant non-major bleeding’ was added to the bleeding outcomes as this was commonly reported in the newer, larger trials,
and does not fit well within major or minor bleeding categories.
The outcomes ’Wound infection’, ’Wound healing’ and ’Reoperation following surgery’ were added as they are deemed important
outcomes for orthopaedic surgeons (Wang 2014).
Calculation of number needed to treat for an additional beneficial outcome (NNTB) and needed to treat for an additional harmful
outcome (NNTH) were removed as the calculations in a meta-analysis setting can be misleading and should be treated with caution.
The method of evaluating study quality has changed since the protocol was published; we used the Cochrane ’Risk of bias’ tool (Higgins
2011). We have also added ’Summary of findings’ tables.
In the ’Sensitivity analysis’ section, we have removed the indication to compare results using a fixed and random-effects model, as we
are using the I2 statistic to decide the appropriateness of the use of the different model types.
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